Involvement	O
of	O
adenylate	O
cyclase	O
and	O
p70	B-Protein
(	I-Protein
S6	I-Protein
)	I-Protein
-	I-Protein
kinase	E-Protein
activation	O
in	O
IL	B-Protein
-	I-Protein
10	E-Protein
up	O
-	O
regulation	O
in	O
human	O
monocytes	O
by	O
gp41	S-Protein
envelope	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	O
gp41	S-Protein
(	O
aa565	O
-	O
647	O
)	O
,	O
the	O
extracellular	O
domain	O
of	O
HIV	O
-	O
1	O
transmembrane	O
glycoprotein	O
,	O
stimulates	O
interleukin	B-Protein
-	I-Protein
10	E-Protein
(	O
IL	B-Protein
-	I-Protein
10	E-Protein
)	O
production	O
in	O
human	O
monocytes	O
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	S-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	E-Protein
up	O
-	O
regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	O
-	O
kappaB	O
pathways	O
.	O

gp41	S-Protein
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
and	O
the	O
adenylate	O
cyclase	O
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	S-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	E-Protein
production	O
in	O
monocytes	O
.	O

In	O
contrast	O
,	O
gp41	S-Protein
failed	O
to	O
stimulate	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
main	O
NF	O
-	O
kappaB	O
-	O
binding	O
site	O
2	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	E-Protein
promoter	O
after	O
addition	O
of	O
gp41	S-Protein
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

Specific	O
inhibitors	O
of	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
(	O
rapamycin	O
)	O
,	O
and	O
Gi	O
protein	O
(	O
pertussis	O
toxin	O
)	O
,	O
prevented	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
production	O
by	O
gp41	S-Protein
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
(	O
wortmannin	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Thus	O
HIV	O
-	O
1	O
gp41	S-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	E-Protein
up	O
-	O
regulation	O
in	O
monocytes	O
may	O
not	O
involve	O
NF	O
-	O
kappaB	O
,	O
MAPK	O
,	O
or	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	O
cyclase	O
and	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
Gi	O
/	O
Go	O
protein	O
to	O
effect	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
activation	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	O
protein	O
Tax	S-Protein
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	S-Protein
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	S-Protein
(	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
)	O
.	O

Whereas	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Tax	S-Protein
-	O
expressing	O
T	O
-	O
cell	O
lines	O
consisted	O
mostly	O
of	O
p50	S-Protein
/	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50	S-Protein
/	O
p50	S-Protein
and	O
p50	S-Protein
/	O
p65	S-Protein
heterodimers	O
.	O

One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	S-Protein
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	S-Protein
expression	O
.	O

Interestingly	O
,	O
the	O
NF	O
-	O
kappaB	O
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	S-Protein
/	O
p50	S-Protein
and	O
p50	S-Protein
/	O
p65	S-Protein
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
a	O
Tax	S-Protein
-	O
independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	O
-	O
kappaB	O
subunit	O
activation	O
.	O

Apoptosis	O
-	O
resistant	O
T	O
cells	O
have	O
a	O
deficiency	O
in	O
NF	O
-	O
kappaB	O
-	O
mediated	O
induction	O
of	O
Fas	B-Protein
ligand	E-Protein
transcription	O
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4	S-Protein
+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B-Protein
ligand	E-Protein
(	O
FasL	S-Protein
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	S-Protein
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
)	O
production	O
is	O
normal	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL	S-Protein
-	O
and	O
a	O
consensus	O
NF	O
-	O
kappaB	O
-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	S-Protein
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	O
-	O
kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FasL	S-Protein
expression	O
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	S-Protein
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF	O
-	O
kappaB	O
deprivation	O
.	O

NF	O
-	O
kappaB	O
regulates	O
Fas	S-Protein
/	O
APO	B-Protein
-	I-Protein
1	E-Protein
/	O
CD95	S-Protein
-	O
and	O
TCR	O
-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF	O
-	O
kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	S-Protein
/	O
APO	B-Protein
-	I-Protein
1	E-Protein
/	O
CD95	S-Protein
-	O
mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF	O
-	O
kappaB	O
subunits	O
p50	S-Protein
and	O
p65	S-Protein
confers	O
resistance	O
against	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	S-Protein
and	O
p65	S-Protein
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	S-Protein
-	O
mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O

Concanavalin	O
A	O
-	O
activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	O
-	O
kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti	O
-	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	O
-	O
kappaB	O
protects	O
against	O
Fas	S-Protein
-	O
mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34	S-Protein
+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34	S-Protein
+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O

We	O
now	O
find	O
that	O
cytokine	O
-	O
driven	O
(	O
granulocyte	O
-	O
macrophage	O
CSF	O
and	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
CD34	S-Protein
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	O
activation	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34	S-Protein
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
CD34	S-Protein
+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
CSF	E-Protein
plus	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic	O
-	O
like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	O
I	O
+	O
/	O
MHC	O
IIbright	O
/	O
CD83	S-Protein
+	O
/	O
CD86	S-Protein
+	O
/	O
CD14	S-Protein
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	S-Protein
and	O
DC	B-Protein
-	I-Protein
CK1	E-Protein
gene	O
expression	O
.	O

Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC	O
-	O
dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O

Comparison	O
of	O
KG1	O
to	O
the	O
PMA	O
-	O
unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-Protein
receptors	I-Protein
1	E-Protein
and	O
2	S-Protein
;	O
PKC	B-Protein
isoforms	I-Protein
alpha	E-Protein
,	O
beta	B-Protein
I	E-Protein
,	O
beta	B-Protein
II	E-Protein
,	O
and	O
mu	S-Protein
;	O
and	O
RelB	S-Protein
,	O
suggesting	O
that	O
these	O
components	O
/	O
pathways	O
are	O
important	O
for	O
DC	O
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34	S-Protein
+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O

IL	B-Protein
-	I-Protein
2	E-Protein
-	O
mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	O
-	O
kappa	O
B	O
or	O
activating	O
protein	O
-	O
1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL	B-Protein
-	I-Protein
2	E-Protein
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL	B-Protein
-	I-Protein
2	E-Protein
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
/	O
or	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	E-Protein
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
does	O
not	O
induce	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
degradation	O
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL	B-Protein
-	I-Protein
2	E-Protein
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL	B-Protein
-	I-Protein
2	E-Protein
neither	O
activates	O
JNK	O
nor	O
increases	O
AP	O
-	O
1	O
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	O
the	O
activation	O
of	O
STAT3	S-Protein
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	O
-	O
kappa	O
B	O
nor	O
AP	O
-	O
1	O
activation	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
2	E-Protein
-	O
mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
(	O
mut	B-Protein
-	I-Protein
I	I-Protein
kappa	I-Protein
B	E-Protein
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	S-Protein
-	O
CD25	S-Protein
+	O
,	O
CD4	S-Protein
-	O
CD8	O
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-Protein
beta	I-Protein
-	I-Protein
chain	E-Protein
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Differential	O
regulation	O
of	O
4E	B-Protein
-	I-Protein
BP1	E-Protein
and	O
4E	B-Protein
-	I-Protein
BP2	E-Protein
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL	O
-	O
60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U	O
-	O
937	O
monoblastic	O
cell	O
line	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	B-Protein
-	I-Protein
BP1	E-Protein
and	O
4E	B-Protein
-	I-Protein
BP2	E-Protein
.	O

Induction	O
of	O
HL	O
-	O
60	O
and	O
U	O
-	O
937	O
cell	O
differentiation	O
into	O
monocytes	O
/	O
macrophages	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E	B-Protein
-	I-Protein
BP1	E-Protein
.	O

Dephosphorylation	O
of	O
4E	B-Protein
-	I-Protein
BP1	E-Protein
was	O
also	O
observed	O
when	O
U	O
-	O
937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
/	O
macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	B-Protein
-	I-Protein
BP1	E-Protein
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	B-Protein
-	I-Protein
BP2	E-Protein
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Stimulation	O
of	O
CD40	S-Protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-	O
mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	S-Protein
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	S-Protein
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O

CD40	S-Protein
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	S-Protein
negative	O
.	O

CD40	S-Protein
expression	O
could	O
be	O
enhanced	O
in	O
CD40	S-Protein
-	O
positive	O
MM	O
by	O
stimulation	O
with	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
but	O
not	O
by	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
1beta	E-Protein
or	O
CD40	S-Protein
triggering	O
.	O

CD40	S-Protein
ligation	O
on	O
MM	O
by	O
CD40L	S-Protein
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	S-Protein
fusion	O
protein	O
up	O
-	O
regulated	O
their	O
expression	O
of	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	E-Protein
and	O
MHC	O
class	O
I	O
and	O
class	O
II	O
molecules	O
and	O
their	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
,	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
a	E-Protein
,	O
and	O
granulocyte	B-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
.	O

Furthermore	O
,	O
CD40	S-Protein
ligation	O
of	O
a	O
HLA	B-Protein
-	I-Protein
A2	E-Protein
+	O
,	O
MelanA	S-Protein
/	O
MART1	S-Protein
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	B-Protein
-	I-Protein
A2	E-Protein
-	O
restricted	O
,	O
MelanA	S-Protein
/	O
MART	B-Protein
-	I-Protein
1	E-Protein
-	O
specific	O
CTL	O
clone	O
.	O

Finally	O
,	O
CD40	S-Protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	S-Protein
-	O
CD40L	S-Protein
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	S-Protein
-	O
positive	O
immunogenic	O
human	O
MMs	O
.	O

Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	O
G	O
immune	O
complexes	O
requires	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome	O
-	O
encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	O
NF	O
-	O
kappaB	O
in	O
the	O
inflammatory	O
model	O
.	O

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
and	O
the	O
CXC	O
chemokine	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	E-Protein
,	O
were	O
substantially	O
reduced	O
.	O

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	O
vascular	O
adhesion	O
molecule	O
,	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	E-Protein
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate	O
-	O
containing	O
liposomes	O
.	O

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O

Lung	O
instillation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
in	O
alveolar	O
macrophage	O
-	O
depleted	O
rats	O
restored	O
the	O
NF	O
-	O
kappaB	O
activation	O
response	O
in	O
whole	O
lung	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
may	O
propagate	O
NF	O
-	O
kappaB	O
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
(	I-Protein
TRAF	I-Protein
)	I-Protein
1	E-Protein
,	O
2	S-Protein
,	O
or	O
3	S-Protein
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT	O
/	O
S	O
in	O
STP	B-Protein
-	I-Protein
A11	E-Protein
as	O
critical	O
for	O
TRAF	O
association	O
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	B-Protein
-	I-Protein
C488	E-Protein
is	O
critical	O
for	O
TRAF	O
association	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	B-Protein
-	I-Protein
C488	E-Protein
induced	O
NF	O
-	O
kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	O
.	O

The	O
HVS	O
STP	B-Protein
-	I-Protein
C488	E-Protein
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
-	O
independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP	B-Protein
-	I-Protein
C488	E-Protein
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat	O
-	O
1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	S-Protein
dominant	O
-	O
negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	O
in	O
STP	B-Protein
-	I-Protein
C488	E-Protein
-	O
mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Regulation	O
of	O
Fas	B-Protein
ligand	E-Protein
expression	O
and	O
cell	O
death	O
by	O
apoptosis	B-Protein
-	I-Protein
linked	I-Protein
gene	I-Protein
4	E-Protein
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	S-Protein
/	O
Fas	B-Protein
ligand	E-Protein
(	O
FasL	S-Protein
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG	O
-	O
4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	O
cell	O
-	O
receptor	O
-	O
induced	O
FasL	S-Protein
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
ALG	B-Protein
-	I-Protein
4	E-Protein
induced	O
transcription	O
of	O
FasL	S-Protein
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG	B-Protein
-	I-Protein
4	E-Protein
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	S-Protein
expression	O
.	O

Fas	S-Protein
/	O
FasL	S-Protein
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	S-Protein
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T	O
-	O
cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	E-Protein
(	O
CAT	S-Protein
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	S-Protein
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7	B-Protein
.	I-Protein
1	E-Protein
molecules	O
.	O

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase	O
-	O
1	O
and	O
-	O
3	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
and	O
partially	O
blocked	O
by	O
Ac	O
-	O
DEVD	O
-	O
fmk	O
,	O
suggesting	O
that	O
SN50	O
-	O
mediated	O
apoptosis	O
is	O
caspase	O
-	O
dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N	O
'	O
-	O
tetrakis	O
[	O
2	O
-	O
pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	B-Protein
ligand	E-Protein
(	O
CD95	S-Protein
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	O
death	O
effector	O
proteases	O
caspase	B-Protein
-	I-Protein
1	E-Protein
-	O
like	O
(	O
IL	O
-	O
1	O
converting	O
enzyme	O
)	O
,	O
caspase	B-Protein
-	I-Protein
3	E-Protein
-	O
like	O
(	O
CPP32	S-Protein
/	O
Yama	S-Protein
/	O
apopain	S-Protein
)	O
,	O
and	O
caspase	B-Protein
-	I-Protein
6	E-Protein
-	O
like	O
and	O
without	O
cleavage	O
of	O
caspase	B-Protein
-	I-Protein
3	E-Protein
substrates	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
DNA	B-Protein
fragmentation	I-Protein
factor	I-Protein
-	I-Protein
45	E-Protein
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50	O
-	O
induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	E-Protein
.	O

Human	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	E-Protein
(	O
TLR2	S-Protein
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	O
-	O
kappaB	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	S-Protein
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	S-Protein
associates	O
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	S-Protein
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	S-Protein
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	S-Protein
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	S-Protein
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	O
-	O
type	O
TLR2	S-Protein
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	S-Protein
-	O
mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
6	E-Protein
,	O
and	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	I-Protein
inducing	I-Protein
kinase	E-Protein
,	O
when	O
coexpressed	O
with	O
TLR2	S-Protein
,	O
abrogate	O
TLR2	S-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	S-Protein
and	O
IL	O
-	O
1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	S-Protein
by	O
DN	O
variants	O
.	O

Activation	O
of	O
the	O
Janus	B-Protein
kinase	I-Protein
3	E-Protein
-	O
STAT5a	S-Protein
pathway	O
after	O
CD40	S-Protein
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O

CD40	S-Protein
/	O
CD40	B-Protein
ligand	E-Protein
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	S-Protein
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	S-Protein
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	S-Protein
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O

After	O
CD40	S-Protein
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
(	O
but	O
not	O
of	O
the	O
AP	O
-	O
1	O
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	S-Protein
is	O
part	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
induced	O
by	O
CD40	S-Protein
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	S-Protein
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	B-Protein
kinase	I-Protein
3	E-Protein
tyrosine	O
kinase	O
was	O
associated	O
with	O
CD40	S-Protein
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	B-Protein
kinase	I-Protein
3	E-Protein
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40	S-Protein
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	S-Protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	S-Protein
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	S-Protein
-	O
induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	S-Protein
ligand	O
+	O
hyper	O
IgM	O
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	S-Protein
-	O
induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA	S-Protein
/	O
NFkappaB1	S-Protein
-	O
binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	O
-	O
binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	S-Protein
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	S-Protein
and	O
NF	B-Protein
-	I-Protein
kappaB1	E-Protein
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	S-Protein
/	O
NF	B-Protein
-	I-Protein
kappaB1	E-Protein
binding	O
complexes	O
.	O

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF	O
-	O
kappaB	O
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

Monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG	S-Protein
-	O
AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin	B-Protein
-	I-Protein
6	E-Protein
(	O
IL	B-Protein
-	I-Protein
6	E-Protein
)	O
and	O
von	B-Protein
Willebrand	I-Protein
factor	E-Protein
(	O
vWF	S-Protein
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
1	E-Protein
,	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
1	E-Protein
,	O
and	O
E	B-Protein
-	I-Protein
selectin	E-Protein
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF	O
-	O
kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
mAECA	O
,	O
but	O
not	O
normal	O
human	O
IgG	S-Protein
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	O
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL	B-Protein
-	I-Protein
6	E-Protein
and	O
vWF	S-Protein
secretion	O
.	O

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF	O
-	O
kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	S-Protein
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	S-Protein
that	O
constitutively	O
associates	O
with	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
1	I-Protein
(	I-Protein
TNFR1	I-Protein
)	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	E-Protein
TRADD	S-Protein
to	O
mediate	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	S-Protein
signaling	O
through	O
TRADD	S-Protein
differs	O
from	O
TNFR1	S-Protein
signaling	O
through	O
TRADD	S-Protein
.	O

LMP1	S-Protein
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	O
-	O
kappaB	O
or	O
synergize	O
with	O
TRADD	S-Protein
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	S-Protein
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	S-Protein
does	O
not	O
require	O
TRADD	S-Protein
residues	O
294	O
to	O
312	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	S-Protein
requires	O
TRADD	S-Protein
residues	O
296	O
to	O
302	O
.	O

LMP1	S-Protein
is	O
partially	O
blocked	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
TRADD	S-Protein
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	S-Protein
,	O
LMP1	S-Protein
can	O
interact	O
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
LMP1	S-Protein
does	O
not	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	S-Protein
or	O
RIP	O
,	O
LMP1	S-Protein
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	S-Protein
,	O
TRADD	S-Protein
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Regulatory	O
effects	O
of	O
interleukin	B-Protein
-	I-Protein
11	E-Protein
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin	B-Protein
-	I-Protein
11	E-Protein
(	O
IL	B-Protein
-	I-Protein
11	E-Protein
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL	B-Protein
-	I-Protein
11	E-Protein
mRNA	O
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL	B-Protein
-	I-Protein
11	E-Protein
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL	B-Protein
-	I-Protein
11	E-Protein
were	O
associated	O
with	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-Protein
-	I-Protein
1	E-Protein
.	O

It	O
is	O
interesting	O
that	O
IL	B-Protein
-	I-Protein
11	E-Protein
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	O
chemokines	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	E-Protein
(	O
MIP	B-Protein
-	I-Protein
2	E-Protein
)	O
and	O
cytokine	O
-	O
inducible	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
;	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
11	E-Protein
did	O
not	O
affect	O
these	O
chemokines	O
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL	B-Protein
-	I-Protein
11	E-Protein
.	O

These	O
data	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
11	E-Protein
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
diminished	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
and	O
reduced	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-Protein
-	I-Protein
1	E-Protein
.	O

ETS	O
transcription	O
factors	O
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
.	O

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	O
necrosis	B-Protein
factor	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
.	O

A	O
reporter	O
construct	O
containing	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
mouse	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
gene	O
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264	O
.	O
7	O
macrophage	O
-	O
like	O
cells	O
.	O

The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	S-Protein
protein	O
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	O
20	O
-	O
bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant	O
-	O
negative	O
ets	O
-	O
binding	O
factor	O
was	O
co	O
-	O
transfected	O
with	O
the	O
reporter	O
gene	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	S-Protein
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264	O
.	O
7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon	B-Protein
-	I-Protein
gamma	E-Protein
inducible	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	O
transcription	O
factors	O
in	O
the	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
.	O

Abnormal	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65	S-Protein
-	O
RelA	S-Protein
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	O
receptor	O
-	O
initiated	O
signaling	O
events	O
and	O
lymphokine	O
production	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
protein	O
complex	O
in	O
lupus	O
T	O
cells	O
.	O

Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	S-Protein
Abs	O
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane	O
-	O
mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	O
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
p65	S-Protein
complexes	O
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	S-Protein
protein	O
levels	O
.	O

As	O
p65	S-Protein
complexes	O
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	S-Protein
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	O
cytokine	O
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
,	O
IL	B-Protein
-	I-Protein
6	E-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
IL	B-Protein
-	I-Protein
10	E-Protein
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	O
-	O
kB	O
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kB	O
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O

The	O
p53	S-Protein
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	S-Protein
molecule	O
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	O
p53	S-Protein
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	O
type	O
p53	S-Protein
that	O
inhibits	O
tumor	O
progression	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	O
type	O
p53	S-Protein
in	O
concert	O
with	O
the	O
nuclear	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Both	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
and	O
NF	O
-	O
kappa	O
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	O
type	O
p53	S-Protein
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation	O
/	O
proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK	B-Protein
-	I-Protein
alpha	E-Protein
,	O
IKK	B-Protein
-	I-Protein
beta	E-Protein
,	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	I-Protein
inducing	I-Protein
kinase	E-Protein
(	O
NIK	S-Protein
)	O
,	O
IKK	B-Protein
-	I-Protein
gamma	E-Protein
(	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	B-Protein
complex	I-Protein
-	I-Protein
associated	I-Protein
protein	E-Protein
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3	O
-	O
fold	O
greater	O
effect	O
on	O
IKK	B-Protein
-	I-Protein
alpha	E-Protein
than	O
on	O
IKK	B-Protein
-	I-Protein
beta	E-Protein
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK	B-Protein
-	I-Protein
beta	E-Protein
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK	B-Protein
-	I-Protein
alpha	E-Protein
and	O
-	B-Protein
beta	E-Protein
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	O
-	O
alpha	O
/	O
beta	O
heterodimer	O
with	O
NIK	S-Protein
,	O
IkappaB	B-Protein
-	I-Protein
alpha	E-Protein
and	O
-	B-Protein
epsilon	E-Protein
in	O
unstimulated	O
cells	O
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	O
to	O
differential	O
patterns	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	E-Protein
and	O
IkappaB	B-Protein
-	I-Protein
epsilon	E-Protein
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	B-Protein
-	I-Protein
alpha	E-Protein
,	O
IKK	B-Protein
-	I-Protein
beta	E-Protein
,	O
and	O
NIK	S-Protein
remained	O
complex	O
-	O
associated	O
.	O

NIK	S-Protein
cannot	O
phosphorylate	O
IkappaB	B-Protein
-	I-Protein
alpha	E-Protein
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	S-Protein
inhibited	O
stimulus	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	B-Protein
-	I-Protein
alpha	E-Protein
or	O
-	B-Protein
beta	E-Protein
.	O

Overexpression	O
of	O
IKK	O
complex	O
-	O
associated	O
protein	O
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS	O
-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	B-Protein
-	I-Protein
Fos	E-Protein
and	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
which	O
stimulates	O
PKC	S-Protein
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5	O
'	O
-	O
(	O
N	O
-	O
ethyl	O
)	O
-	O
carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c	B-Protein
-	I-Protein
Fos	E-Protein
and	O
Jun	S-Protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
both	O
c	B-Protein
-	I-Protein
Fos	E-Protein
and	O
Jun	S-Protein
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c	B-Protein
-	I-Protein
Fos	E-Protein
)	O
or	O
decrease	O
(	O
Jun	S-Protein
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP	O
-	O
1	O
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	S-Protein
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	S-Protein
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP	O
-	O
1	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
oncoprotein	O
.	O

The	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	B-Protein
acid	I-Protein
receptor	E-Protein
.	O

The	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA	O
-	O
binding	O
domain	O
relative	O
to	O
that	O
of	O
c	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
protein	O
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D	O
-	O
box	O
of	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
protein	O
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor	O
-	O
receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	O
61	O
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	E-Protein
function	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	S-Protein
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H	B-Protein
-	I-Protein
2Kb	E-Protein
,	O
is	O
indistinguishable	O
from	O
the	O
p50	S-Protein
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	S-Protein
/	O
p50	S-Protein
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	B-Protein
-	I-Protein
rel	E-Protein
and	O
v	B-Protein
-	I-Protein
rel	E-Protein
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	S-Protein
/	O
p50	S-Protein
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1	S-Protein
/	O
p50	S-Protein
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild	O
-	O
type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	S-Protein
/	O
p50	S-Protein
,	O
c	B-Protein
-	E-Protein
and	O
v	B-Protein
-	I-Protein
rel	E-Protein
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	S-Protein
+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1	O
-	O
induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H	B-Protein
-	I-Protein
2Kb	E-Protein
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
.	O

NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	S-Protein
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	S-Protein
expression	O
on	O
the	O
interaction	O
of	O
NF	O
-	O
kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	S-Protein
expression	O
vector	O
.	O

Tax	S-Protein
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-	O
linking	O
using	O
a	O
palindromic	O
NF	O
-	O
kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	B-Protein
beta	E-Protein
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2	O
.	O
10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	S-Protein
expressing	O
cells	O
the	O
85	O
-	O
kDa	O
protein	O
and	O
a	O
92	O
-	O
kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	S-Protein
protein	O
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	E-Protein
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	S-Protein
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
and	O
thus	O
change	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Anti	O
-	O
CD2	S-Protein
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	S-Protein
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	O
-	O
CD2	S-Protein
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	O
-	O
CD2	S-Protein
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	O
-	O
CD2	S-Protein
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	S-Protein
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	S-Protein
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	S-Protein
with	O
its	O
natural	O
ligand	O
,	O
LFA	B-Protein
-	I-Protein
3	E-Protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

v	B-Protein
-	I-Protein
erbA	E-Protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c	B-Protein
-	I-Protein
erbA	E-Protein
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	S-Protein
.	O

The	O
v	B-Protein
-	I-Protein
erbA	E-Protein
oncoprotein	O
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3	O
/	O
T4	O
)	O
receptor	O
c	B-Protein
-	I-Protein
erbA	E-Protein
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v	B-Protein
-	I-Protein
erbA	E-Protein
and	O
c	B-Protein
-	I-Protein
erbA	E-Protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	O
-	O
specific	O
carbonic	B-Protein
anhydrase	I-Protein
II	E-Protein
(	O
CAII	S-Protein
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v	B-Protein
-	I-Protein
erbA	E-Protein
.	O

This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	S-Protein
transcription	O
by	O
the	O
v	B-Protein
-	I-Protein
erbA	E-Protein
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v	B-Protein
-	I-Protein
erbA	E-Protein
oncoprotein	O
and	O
the	O
c	B-Protein
-	I-Protein
erbA	E-Protein
/	O
T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	B-Protein
-	I-Protein
erbA	E-Protein
activity	O
is	O
dominant	O
over	O
v	B-Protein
-	I-Protein
erbA	E-Protein
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v	B-Protein
-	I-Protein
erbA	E-Protein
-	O
mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	S-Protein
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	O
-	O
responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	S-Protein
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O

The	O
c	B-Protein
-	I-Protein
erbA	E-Protein
-	O
dependent	O
activation	O
of	O
this	O
CAII	S-Protein
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	B-Protein
-	I-Protein
erbA	E-Protein
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v	B-Protein
-	I-Protein
erbA	E-Protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

NF	O
-	O
X2	O
that	O
binds	O
to	O
the	O
DRA	O
X2	O
-	O
box	O
is	O
activator	O
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c	B-Protein
-	I-Protein
Jun	E-Protein
.	O

Human	O
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2	O
-	O
box	O
to	O
which	O
nuclear	O
factor	O
X2	O
(	O
NF	O
-	O
X2	O
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	O
-	O
X2	O
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c	B-Protein
-	I-Protein
Jun	E-Protein
protein	O
,	O
which	O
together	O
with	O
c	B-Protein
-	I-Protein
Fos	E-Protein
forms	O
the	O
heterodimeric	O
activator	O
protein	O
-	O
1	O
transcription	O
complex	O
.	O

Whereas	O
c	B-Protein
-	I-Protein
Fos	E-Protein
/	O
c	B-Protein
-	I-Protein
Jun	E-Protein
heterodimers	O
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2	O
-	O
box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c	B-Protein
-	I-Protein
Fos	E-Protein
/	O
c	B-Protein
-	I-Protein
Jun	E-Protein
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	S-Protein
gene	O
expression	O
.	O

Regulation	O
of	O
jun	S-Protein
and	O
fos	S-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M	O
-	O
CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	S-Protein
and	O
fos	S-Protein
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c	B-Protein
-	I-Protein
jun	E-Protein
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	O
recombinant	O
M	O
-	O
CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c	B-Protein
-	I-Protein
jun	E-Protein
mRNA	O
levels	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	O
-	O
CSF	O
regulates	O
c	B-Protein
-	I-Protein
jun	E-Protein
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
c	B-Protein
-	I-Protein
jun	E-Protein
transcripts	O
.	O

M	O
-	O
CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun	B-Protein
-	I-Protein
B	E-Protein
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c	B-Protein
-	I-Protein
jun	E-Protein
.	O

We	O
further	O
demonstrate	O
that	O
M	O
-	O
CSF	O
increases	O
c	B-Protein
-	I-Protein
fos	E-Protein
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	E-Protein
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	B-Protein
-	I-Protein
B	E-Protein
gene	O
.	O

Moreover	O
,	O
M	O
-	O
CSF	O
-	O
induced	O
expression	O
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra	B-Protein
-	I-Protein
1	E-Protein
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	B-Protein
-	I-Protein
fos	E-Protein
and	O
fos	B-Protein
-	I-Protein
B	E-Protein
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	O
-	O
CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	O
/	O
fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

cAMP	O
-	O
dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	S-Protein
and	O
JunB	S-Protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP	O
-	O
1	O
proteins	O
.	O

We	O
demonstrate	O
that	O
JunD	S-Protein
,	O
a	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	S-Protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	O
-	O
,	O
phorbol	O
ester	O
-	O
,	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
inducible	O
enhancer	O
,	O
and	O
JunD	S-Protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
complex	O
,	O
JunB	S-Protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	S-Protein
.	O

As	O
a	O
homodimer	O
JunB	S-Protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c	B-Protein
-	I-Protein
Fos	E-Protein
,	O
high	O
-	O
affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	S-Protein
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A	O
-	O
dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP	O
-	O
1	O
-	O
related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP	O
-	O
dependent	O
second	O
-	O
messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	S-Protein
and	O
other	O
AP	O
-	O
1	O
-	O
related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB	O
-	O
985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	S-Protein
on	O
the	O
cell	O
surface	O
,	O
PLB	O
-	O
985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
strain	O
IIIB	O
.	O

PLB	O
-	O
IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid	O
-	O
specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c	B-Protein
-	I-Protein
fms	E-Protein
proto	O
-	O
oncogene	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB	O
-	O
985	O
.	O

However	O
,	O
in	O
PLB	O
-	O
IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	O
-	O
kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	B-Protein
beta	E-Protein
(	O
IFN	B-Protein
-	I-Protein
beta	E-Protein
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
proteins	O
.	O

Inducibility	O
of	O
endogenous	O
IFN	B-Protein
-	I-Protein
beta	E-Protein
and	O
IFN	B-Protein
-	I-Protein
alpha	E-Protein
RNA	O
was	O
also	O
increased	O
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

The	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
,	O
but	O
not	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	O
kinase	O
C	O
in	O
the	O
interleukin	B-Protein
2	E-Protein
promoter	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-	O
related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	O
in	O
induction	O
of	O
the	O
interleukin	B-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar	O
-	O
5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	O
induction	O
of	O
IL	B-Protein
-	I-Protein
2	E-Protein
mRNA	O
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-Protein
acetyltransferase	E-Protein
activity	O
in	O
Ar	O
-	O
5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT	B-Protein
-	I-Protein
1	E-Protein
,	O
Oct	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	O
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
site	O
located	O
at	O
-	O
150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c	B-Protein
-	I-Protein
fos	E-Protein
and	O
c	B-Protein
-	I-Protein
jun	E-Protein
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
differentiation	O
,	O
with	O
c	B-Protein
-	I-Protein
jun	E-Protein
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP	O
-	O
1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP	O
-	O
1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP	O
-	O
1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP	O
-	O
1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c	B-Protein
-	I-Protein
jun	E-Protein
expression	O
,	O
the	O
generation	O
of	O
AP	O
-	O
1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	B-Protein
nuclear	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
(	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	B-Protein
cofactor	I-Protein
of	I-Protein
HNF	I-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
(	O
DCoH	S-Protein
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH	S-Protein
-	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	S-Protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	S-Protein
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	S-Protein
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	S-Protein
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	S-Protein
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	S-Protein
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	S-Protein
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	S-Protein
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	S-Protein
plus	O
two	O
p50s	S-Protein
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	S-Protein
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

However	O
,	O
as	O
NF	O
-	O
kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	O
-	O
kappa	O
B	O
should	O
be	O
considered	O
.	O

ETS1	S-Protein
transactivates	O
the	O
human	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	S-Protein
and	O
ELF1	S-Protein
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-	O
47	O
to	O
-	O
40	O
upstream	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	S-Protein
,	O
but	O
not	O
ELF1	S-Protein
,	O
can	O
transactivate	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-	O
GGAA	O
-	O
to	O
-	O
GGAT	O
-	O
prevents	O
the	O
binding	O
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	O
of	O
ETS1	S-Protein
.	O

The	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	S-Protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	S-Protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	S-Protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
rabbit	O
15	B-Protein
-	I-Protein
lipoxygenase	E-Protein
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O

The	O
15	B-Protein
-	I-Protein
lipoxygenase	E-Protein
(	O
lox	S-Protein
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15	B-Protein
-	I-Protein
lox	E-Protein
gene	O
contains	O
sequences	O
which	O
down	O
-	O
regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	O
cell	O
lines	O
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'	O
silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non	O
-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	S-Protein
promoter	O
fragment	O
.	O

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
Sp1	S-Protein
transcription	O
factors	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
-	O
induced	O
,	O
dendritic	O
cell	O
-	O
T	O
-	O
cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	O
factor	O
Sp1	S-Protein
to	O
drive	O
the	O
HIV	O
-	O
1	O
promoter	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV	O
-	O
1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O

These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki	O
-	O
67	O
cell	O
cycle	O
antigen	O
.	O

The	O
expression	O
and	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	S-Protein
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	O
cells	O
lack	O
active	O
NF	O
-	O
kappa	O
B	O
but	O
express	O
Sp1	S-Protein
as	O
expected	O
.	O

DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	S-Protein
,	O
p50	S-Protein
,	O
and	O
p65	S-Protein
.	O

However	O
,	O
DCs	O
lack	O
Sp1	S-Protein
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
purified	O
DCs	O
.	O

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	S-Protein
occurs	O
in	O
the	O
heterologous	O
DC	O
-	O
T	O
-	O
cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV	O
-	O
1	O
.	O

Therefore	O
,	O
HIV	O
-	O
1	O
-	O
induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV	O
-	O
1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Costimulation	O
requirement	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
requires	O
T	O
-	O
cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	O
and	O
the	O
auxiliary	O
receptor	O
CD28	S-Protein
.	O

Several	O
transcription	O
factors	O
participate	O
in	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP	O
-	O
1	O
-	O
like	O
factors	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP	O
-	O
1	O
protein	O
c	B-Protein
-	I-Protein
Jun	E-Protein
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O

Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	O
,	O
the	O
MAP	O
kinase	O
-	O
related	O
kinase	O
that	O
phosphorylates	O
the	O
transactivation	O
domain	O
of	O
c	B-Protein
-	I-Protein
Jun	E-Protein
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	O
and	O
CD28	S-Protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	O
kappa	O
B	O
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	O
activation	O
and	O
c	B-Protein
-	I-Protein
Jun	E-Protein
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP	O
-	O
1	O
/	O
NF	O
-	O
kappa	O
B	O
pathway	O
.	O

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-Protein
protein	I-Protein
I	I-Protein
kappa	I-Protein
B	E-Protein
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
to	O
release	O
NF	O
kappa	O
B	O
.	O

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B	O
-	O
I	B-Protein
kappa	I-Protein
B	E-Protein
complex	O
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
was	O
observed	O
upon	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	O
Factor	B-Protein
VII	I-Protein
/	I-Protein
VIIa	E-Protein
to	O
the	O
tissue	B-Protein
factor	I-Protein
(	I-Protein
TF	I-Protein
)	I-Protein
receptor	E-Protein
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	S-Protein
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	S-Protein
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	B-Protein
-	I-Protein
Rel	E-Protein
/	O
p65	S-Protein
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	S-Protein
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	S-Protein
activity	O
and	O
TF	S-Protein
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	B-Protein
-	I-Protein
Rel	E-Protein
/	O
p65	S-Protein
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	S-Protein
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	S-Protein
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	B-Protein
-	I-Protein
Rel	E-Protein
/	O
p65	S-Protein
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

CIITA	S-Protein
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	O
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	O
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	B-Protein
class	I-Protein
II	I-Protein
transactivator	E-Protein
(	O
CIITA	S-Protein
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	S-Protein
transcripts	O
while	O
MHC	O
class	O
II	O
-	O
negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	O
.	O

The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	O
CIITA	S-Protein
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	S-Protein
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O

Identification	O
of	O
an	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
-	O
associated	O
protein	O
kinase	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	O
sites	O
on	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	O
kappa	O
B	O
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
phosphorylation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS	O
-	O
stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
-	O
bound	O
kinase	O
activity	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Mutational	O
analyses	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	O
sites	O
by	O
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
blocked	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
in	O
a	O
cell	O
-	O
free	O
system	O
using	O
THP	O
-	O
1	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
.	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
complex	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
6	E-Protein
gene	O
by	O
interferon	B-Protein
-	I-Protein
gamma	E-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
1	E-Protein
,	O
NF	O
kappa	O
B	O
,	O
and	O
Sp1	S-Protein
transcription	O
factors	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon	B-Protein
-	I-Protein
gamma	E-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
)	O
/	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
of	O
human	O
interleukin	B-Protein
-	I-Protein
6	E-Protein
(	O
IL	B-Protein
-	I-Protein
6	E-Protein
)	O
gene	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Functional	O
studies	O
with	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
and	O
/	O
or	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-	O
73	O
and	O
-	O
36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-	O
181	O
and	O
-	O
73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-	O
224	O
,	O
which	O
was	O
inducible	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
alone	O
.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	O
kappa	O
B	O
activation	O
by	O
the	O
p50	S-Protein
/	O
p65	S-Protein
heterodimers	O
.	O

Synergistic	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	E-Protein
gene	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
in	O
monocytic	O
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF	B-Protein
-	I-Protein
1	E-Protein
and	O
NF	O
kappa	O
B	O
p65	S-Protein
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
.	O

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	O
Sp1	S-Protein
factor	O
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
.	O

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	O
-	O
I	O
tax	S-Protein
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
T	O
-	O
cell	O
lines	O
.	O

The	O
HTLV	O
-	O
I	O
transcriptional	O
activator	O
tax	S-Protein
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	B-Protein
-	I-Protein
beta	E-Protein
)	O
gene	O
induction	O
.	O

Tax	O
-	O
expressing	O
cell	O
lines	O
produce	O
LT	O
biologic	O
activity	O
.	O

An	O
LT	O
promoter	O
(	O
LT	O
-	O
293	O
)	O
CAT	S-Protein
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	O
-	O
producing	O
C81	O
-	O
66	O
-	O
45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	O
tax	S-Protein
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1	O
-	O
CAT	S-Protein
)	O
was	O
inactive	O
in	O
C81	O
-	O
66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
LT	O
gene	O
expression	O
.	O

Tax	S-Protein
was	O
transfected	O
into	O
HTLV	O
-	O
I	O
-	O
negative	O
human	O
T	O
-	O
cell	O
lines	O
.	O

Jurkat	O
T	O
cells	O
stably	O
expressing	O
tax	S-Protein
contained	O
elevated	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O

Tax	S-Protein
co	O
-	O
transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV	O
-	O
I	O
-	O
LTR	O
-	O
CAT	S-Protein
and	O
kappa	O
B	O
-	O
fos	S-Protein
-	O
CAT	S-Protein
and	O
also	O
activated	O
LT	O
-	O
293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	S-Protein
induced	O
LT	O
-	O
293	O
activity	O
by	O
two	O
-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1	O
-	O
CAT	S-Protein
.	O

The	O
increase	O
in	O
LT	O
-	O
293	O
CAT	S-Protein
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	O
-	O
I	O
tax	S-Protein
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T	O
-	O
cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T	O
-	O
lymphocytes	O
.	O

The	O
regulatory	O
role	O
of	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	O
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T	O
-	O
cells	O
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
lck	S-Protein
and	O
fyn	S-Protein
(	O
4	O
-	O
and	O
3	O
-	O
fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
,	O
notably	O
phospholipase	B-Protein
C	I-Protein
gamma	I-Protein
1	E-Protein
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2	O
+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	S-Protein
PTPase	O
and	O
was	O
not	O
observed	O
in	O
CD45	S-Protein
-	O
deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O

In	O
the	O
CD45	S-Protein
-	O
negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	E-Protein
gene	O
and	O
accumulation	O
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T	O
-	O
lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	S-Protein
antigen	O
and	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
-	I-Protein
chain	E-Protein
(	O
CD25	S-Protein
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T	O
-	O
cell	O
antigen	O
receptor	O
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	B-Protein
2	E-Protein
production	O
.	O

Pervanadate	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	O
factor	O
.	O

We	O
thus	O
conclude	O
that	O
PTPases	O
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T	O
-	O
lymphocyte	O
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

The	O
interleukin	B-Protein
-	I-Protein
8	E-Protein
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin	B-Protein
-	I-Protein
8	E-Protein
(	O
IL	B-Protein
-	I-Protein
8	E-Protein
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL	B-Protein
-	I-Protein
8	E-Protein
promoters	O
,	O
the	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP	O
-	O
1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-	O
mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP	O
-	O
1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	O
-	O
JunD	S-Protein
or	O
c	B-Protein
-	I-Protein
Fos	E-Protein
antibody	O
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B	O
-	O
like	O
site	O
binding	O
complexes	O
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	O
against	O
the	O
human	O
Rel	O
family	O
proteins	O
(	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
p65	S-Protein
,	O
p50	S-Protein
,	O
and	O
p49	S-Protein
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	O
-	O
kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL	B-Protein
-	I-Protein
8	E-Protein
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	B-Protein
kappa	I-Protein
B	E-Protein
site	O
are	O
FK506	O
-	O
sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL	B-Protein
-	I-Protein
2	E-Protein
NF	B-Protein
-	I-Protein
AT	E-Protein
and	O
NFIL	B-Protein
-	I-Protein
2A	E-Protein
sites	O
and	O
Ig	B-Protein
kappa	I-Protein
B	E-Protein
site	O
,	O
but	O
also	O
the	O
IL	B-Protein
-	I-Protein
8	E-Protein
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O

Monocyte	O
tethering	O
by	O
P	B-Protein
-	I-Protein
selectin	E-Protein
regulates	O
monocyte	B-Protein
chemotactic	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
secretion	O
.	O

Signal	O
integration	O
and	O
NF	O
-	O
kappa	O
B	O
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	O
monocytes	O
to	O
P	B-Protein
-	I-Protein
selectin	E-Protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	O
tethering	O
factor	O
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-Protein
chemotactic	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
(	O
MCP	B-Protein
-	I-Protein
1	E-Protein
)	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet	O
-	O
activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti	O
-	O
P	B-Protein
-	I-Protein
selectin	E-Protein
mAb	O
that	O
prevents	O
P	B-Protein
-	I-Protein
selectin	E-Protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	E-Protein
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P	B-Protein
-	I-Protein
selectin	E-Protein
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
MCP	B-Protein
-	I-Protein
1	E-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O

These	O
results	O
demonstrate	O
that	O
P	B-Protein
-	I-Protein
selectin	E-Protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

HMG	B-Protein
-	I-Protein
I	E-Protein
binds	O
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	O
protein	O
HMG	B-Protein
-	I-Protein
I	E-Protein
to	O
the	O
human	O
gamma	O
-	O
globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG	B-Protein
-	I-Protein
I	E-Protein
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma	O
-	O
globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	O
factor	O
GATA	B-Protein
-	I-Protein
1	E-Protein
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-	O
175	O
T	O
-	O
C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG	B-Protein
-	I-Protein
I	E-Protein
results	O
in	O
overexpression	O
of	O
gamma	O
-	O
globin	O
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up	O
-	O
regulation	O
of	O
the	O
gamma	O
-	O
globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG	B-Protein
-	I-Protein
I	E-Protein
does	O
not	O
bind	O
to	O
this	O
mutant	O
sequence	O
.	O

A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis	O
-	O
elements	O
demonstrates	O
HMG	B-Protein
-	I-Protein
I	E-Protein
binding	O
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG	B-Protein
-	I-Protein
I	E-Protein
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	O
complexes	O
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
promoter	O
activity	O
by	O
AML1	O
-	O
related	O
transcription	O
factor	O
,	O
PEBP2	O
.	O

The	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	O
enhancer	O
binding	O
-	O
protein	O
2	O
(	O
PEBP2	O
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O
alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	S-Protein
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-Protein
A1	E-Protein
(	O
an	O
alpha	O
A	O
-	O
gene	O
product	O
)	O
and	O
alpha	B-Protein
B1	E-Protein
and	O
alpha	B-Protein
B2	E-Protein
(	O
two	O
alpha	O
B	O
-	O
encoded	O
isomers	O
)	O
for	O
their	O
effects	O
on	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
.	O

PEBP2	B-Protein
alpha	I-Protein
A1	E-Protein
,	O
alpha	B-Protein
B1	E-Protein
,	O
and	O
alpha	B-Protein
B2	E-Protein
proteins	O
bound	O
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
.	O

PEBP2	B-Protein
alpha	I-Protein
A1	E-Protein
and	O
alpha	B-Protein
B1	E-Protein
enhanced	O
the	O
expression	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
/	O
phytohemagglutinin	S-Protein
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-Protein
B2	E-Protein
.	O

Coexpression	O
of	O
alpha	B-Protein
B1	E-Protein
and	O
alpha	B-Protein
B2	E-Protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-Protein
B1	E-Protein
/	O
alpha	B-Protein
B2	E-Protein
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	O
site	O
-	O
binding	O
protein	O
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	O
alpha	B-Protein
A1	E-Protein
antibodies	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	O
alpha	O
A	O
,	O
alpha	O
B	O
(	B-Protein
AML1	I-Protein
)	E-Protein
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	O
in	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	O
isoforms	O
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

Differential	O
induction	O
of	O
the	O
NF	O
-	O
AT	O
complex	O
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O

Stimulation	O
of	O
human	O
CD4	S-Protein
+	O
T	O
-	O
cell	O
clones	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	O
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	O
and	O
CD25	O
receptors	O
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL	B-Protein
-	I-Protein
2	E-Protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	O
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF	B-Protein
-	I-Protein
1	E-Protein
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O

The	O
inducible	O
factors	O
NK	O
-	O
kappa	O
B	O
,	O
beta	O
E2	O
,	O
CD28RC	S-Protein
,	O
and	O
AP	O
-	O
1	O
are	O
not	O
expressed	O
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	O
-	O
AT	O
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	O
factors	O
that	O
regulates	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	S-Protein
protein	O
.	O

The	O
IE2	S-Protein
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	S-Protein
)	O
dramatically	O
suppressed	O
this	O
IE2	S-Protein
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	S-Protein
,	O
Rb	S-Protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	S-Protein
specifically	O
interacts	O
with	O
IE2	S-Protein
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	S-Protein
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	S-Protein
.	O

Our	O
results	O
suggest	O
that	O
Rb	S-Protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF	B-Protein
-	I-Protein
1	E-Protein
and	O
its	O
repressor	O
RAZ	S-Protein
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-Protein
ZLF	I-Protein
-	I-Protein
1	E-Protein
gene	O
product	O
,	O
ZEBRA	S-Protein
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	S-Protein
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF	B-Protein
-	I-Protein
1	E-Protein
locus	O
and	O
the	O
adjacent	O
BRLF	B-Protein
-	I-Protein
1	E-Protein
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ZEBRA	S-Protein
protein	O
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA	B-Protein
-	I-Protein
1	E-Protein
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp	O
/	O
Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

Transcripts	O
encoding	O
gp350	B-Protein
/	I-Protein
220	E-Protein
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP	B-Protein
-	I-Protein
2A	E-Protein
or	O
EBER	B-Protein
-	I-Protein
1	E-Protein
loci	O
in	O
infected	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	O
of	O
Sp1	S-Protein
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	S-Protein
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	S-Protein
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	S-Protein
and	O
interleukin	B-Protein
2	E-Protein
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	S-Protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	S-Protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	S-Protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	S-Protein
,	O
and	O
Sp1	S-Protein
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	O
terminus	O
of	O
CIITA	S-Protein
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	O
combined	O
immune	O
deficiency	O
.	O

Type	O
II	O
major	O
histocompatibility	O
complex	O
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	O
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	O
class	O
II	O
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	O
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	S-Protein
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	S-Protein
is	O
an	O
MHC	O
class	O
II	O
gene	O
-	O
specific	O
transcription	O
activator	O
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	O
-	O
terminal	O
acidic	O
domain	O
(	O
amino	O
acids	O
26	O
-	O
137	O
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	O
viral	O
transcription	O
-	O
activating	O
domain	O
.	O

The	O
specificity	O
of	O
CIITA	S-Protein
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C	O
-	O
terminal	O
residues	O
(	O
amino	O
acids	O
317	O
-	O
1130	O
)	O
.	O

The	O
transactivation	O
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	B-Protein
alpha	E-Protein
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	S-Protein
dependent	O
.	O

Since	O
CIITA	S-Protein
overexpression	O
in	O
normal	O
cells	O
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	S-Protein
expression	O
serves	O
as	O
the	O
on	O
-	O
off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
in	O
lpr	O
CD4	S-Protein
-	O
CD8	O
-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
binding	O
factor	O
.	O

The	O
inert	O
quality	O
of	O
MRL	O
-	O
Ipr	O
/	O
Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4	S-Protein
-	O
CD8	O
-	O
(	O
CD4	O
-	O
8	O
-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL	B-Protein
-	I-Protein
2	E-Protein
in	O
response	O
to	O
TCR	O
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	O
-	O
mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	S-Protein
and	O
CD3	B-Protein
zeta	E-Protein
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
(	O
p50	S-Protein
-	O
p65	S-Protein
heterodimer	O
)	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
factors	O
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF	O
-	O
AT	O
complex	O
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF	O
-	O
AT	O
-	O
binding	O
factor	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF	O
-	O
AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

GM	B-Protein
-	I-Protein
CSF	E-Protein
and	O
IL	B-Protein
-	I-Protein
2	E-Protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	O
-	O
like	O
signals	O
.	O

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
4	E-Protein
gene	O
transcription	O
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	S-Protein
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK	O
-	O
1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV	O
-	O
1	O
transactivator	O
protein	O
,	O
tax	S-Protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
and	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	S-Protein
activates	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
through	O
the	O
CK	O
-	O
1	O
/	O
CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
for	O
tax	S-Protein
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK	O
-	O
1	O
/	O
CD28RE	O
of	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
CD28RE	O
and	O
the	O
IL	B-Protein
-	I-Protein
3	E-Protein
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
and	O
IL	B-Protein
-	I-Protein
2	E-Protein
respond	O
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
gene	O
.	O

Murine	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
1	I-Protein
alpha	E-Protein
(	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	S-Protein
,	O
LD78	S-Protein
,	O
or	O
AT464	S-Protein
)	O
are	O
members	O
of	O
the	O
-	O
C	O
-	O
C	O
family	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
chemokines	O
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	O
-	O
derived	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
/	O
GOS19	S-Protein
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	E-Protein
/	O
GOS19	S-Protein
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK	O
-	O
1	O
family	O
)	O
affect	O
the	O
GOS19	S-Protein
promoter	O
.	O

One	O
member	O
,	O
ICK	B-Protein
-	I-Protein
1A	E-Protein
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK	O
-	O
1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP	O
-	O
1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK	O
-	O
1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	O
-	O
migrating	O
protein	O
-	O
DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK	O
-	O
1	O
binding	O
inactivates	O
the	O
GOS19	O
.	O
1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

Ligand	O
-	O
dependent	O
repression	O
of	O
the	O
erythroid	O
transcription	O
factor	O
GATA	B-Protein
-	I-Protein
1	E-Protein
by	O
the	O
estrogen	B-Protein
receptor	E-Protein
.	O

High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha	B-Protein
-	E-Protein
and	O
beta	B-Protein
-	I-Protein
globin	E-Protein
,	O
band	O
3	O
,	O
band	O
4	O
.	O
1	O
,	O
and	O
the	O
erythroid	O
cell	O
-	O
specific	O
histone	O
H5	S-Protein
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA	B-Protein
-	I-Protein
1	E-Protein
,	O
an	O
erythroid	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA	B-Protein
-	I-Protein
1	E-Protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-Protein
receptor	E-Protein
(	O
ER	S-Protein
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4	O
-	O
hydroxytamoxifen	O
.	O

ER	S-Protein
-	O
mediated	O
repression	O
of	O
GATA	B-Protein
-	I-Protein
1	E-Protein
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA	B-Protein
-	I-Protein
1	E-Protein
.	O

GATA	B-Protein
-	I-Protein
1	E-Protein
and	O
ER	S-Protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	B-Protein
-	I-Protein
1	E-Protein
and	O
ER	S-Protein
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA	B-Protein
-	I-Protein
1	E-Protein
and	O
the	O
ER	S-Protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
of	O
GATA	B-Protein
-	I-Protein
1	E-Protein
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA	B-Protein
-	I-Protein
1	E-Protein
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
ER	S-Protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
pp90rsk	O
and	O
early	B-Protein
growth	I-Protein
response	I-Protein
-	I-Protein
1	E-Protein
gene	O
expression	O
by	O
pokeweed	O
mitogen	O
in	O
human	O
B	O
cells	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
on	O
the	O
induction	O
of	O
early	B-Protein
growth	I-Protein
response	I-Protein
-	I-Protein
1	E-Protein
gene	O
(	O
EGR	B-Protein
-	I-Protein
1	E-Protein
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O

PWM	O
regulates	O
EGR	B-Protein
-	I-Protein
1	E-Protein
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR	B-Protein
-	I-Protein
1	E-Protein
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	B-Protein
acetyltransferase	E-Protein
(	O
CAT	S-Protein
)	O
gene	O
demonstrated	O
that	O
PWM	O
induced	O
EGR	B-Protein
-	I-Protein
1	E-Protein
transcription	O
is	O
conferred	O
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR	B-Protein
-	I-Protein
1	E-Protein
promoter	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	O
kinase	O
(	O
pp90rsk	O
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	O
and	O
serum	B-Protein
response	I-Protein
factor	E-Protein
(	O
SRF	S-Protein
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	O
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR	B-Protein
-	I-Protein
1	E-Protein
induction	O
in	O
normal	O
human	O
B	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
controls	O
expression	O
of	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

Phorbol	O
ester	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
induction	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
and	O
the	O
activation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65	O
-	O
kilodalton	O
transactivating	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
with	O
p65	S-Protein
restores	O
intracellular	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
expression	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	S-Protein
plus	O
CD28	S-Protein
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	S-Protein
and	O
CD28	S-Protein
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	B-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
-	O
dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O

Long	O
-	O
lasting	O
IL	B-Protein
-	I-Protein
2	E-Protein
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	E-Protein
(	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	S-Protein
+	O
CD28	S-Protein
activation	O
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	S-Protein
/	O
p50	S-Protein
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B	O
-	O
specific	O
complexes	O
were	O
identified	O
as	O
NF	O
-	O
kappa	O
B	O
p50	S-Protein
-	O
p65	S-Protein
heterodimer	O
and	O
putative	O
c	B-Protein
-	I-Protein
Rel	E-Protein
homodimer	O
or	O
c	B-Protein
-	I-Protein
Rel	E-Protein
-	O
p65	S-Protein
heterodimer	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	S-Protein
+	O
CD28	S-Protein
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL	B-Protein
-	I-Protein
2	E-Protein
secretion	O
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	S-Protein
+	O
CD28	S-Protein
.	O

Synergism	O
between	O
the	O
CD3	O
antigen	O
-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	O
/	O
TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and	O
/	O
or	O
CD2	O
proteins	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and	O
/	O
or	O
sn	O
-	O
1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen	O
-	O
derived	O
signals	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	O
-	O
binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	S-Protein
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
block	O
CD11b	S-Protein
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL	O
-	O
60	O
granulocytes	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	S-Protein
and	O
p65	S-Protein
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	S-Protein
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide	O
-	O
differentiated	O
HL	O
-	O
60	O
leukemia	O
cells	O
stimulated	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	S-Protein
integrin	O
expression	O
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O

Furthermore	O
,	O
the	O
p65	S-Protein
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	S-Protein
that	O
was	O
produced	O
by	O
formyl	O
-	O
met	O
-	O
leu	O
-	O
phe	O
and	O
TPA	O
.	O

However	O
,	O
the	O
p65	S-Protein
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	S-Protein
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Human	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
2	E-Protein
gene	O
.	O

Intron	O
-	O
exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5	O
'	O
-	O
flanking	O
region	O
.	O

Interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
2	E-Protein
(	O
IRF	B-Protein
-	I-Protein
2	E-Protein
)	O
is	O
a	O
transcriptional	O
regulatory	O
protein	O
that	O
terminates	O
interferon	B-Protein
beta	E-Protein
expression	O
initiated	O
by	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF	B-Protein
-	I-Protein
2	E-Protein
gene	O
,	O
determined	O
the	O
intron	O
-	O
exon	O
structure	O
of	O
the	O
human	O
IRF	B-Protein
-	I-Protein
2	E-Protein
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF	B-Protein
-	I-Protein
2	E-Protein
gene	O
on	O
human	O
chromosome	O
4	O
.	O

The	O
IRF	B-Protein
-	I-Protein
2	E-Protein
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	O
TATA	O
box	O
.	O

When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	O
by	O
both	O
interferons	O
(	O
interferon	B-Protein
-	I-Protein
alpha	E-Protein
and	O
-	B-Protein
gamma	E-Protein
)	O
and	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF	B-Protein
-	I-Protein
2	E-Protein
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
,	O
interferon	B-Protein
beta	E-Protein
,	O
and	O
interferon	O
-	O
inducible	O
genes	O
.	O

These	O
data	O
suggest	O
that	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	E-Protein
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	O
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF	B-Protein
-	I-Protein
2	E-Protein
.	O

Overproduction	O
of	O
NFKB2	S-Protein
(	O
lyt	B-Protein
-	I-Protein
10	E-Protein
)	O
and	O
c	B-Protein
-	I-Protein
Rel	E-Protein
:	O
a	O
mechanism	O
for	O
HTLV	O
-	O
I	O
Tax	S-Protein
-	O
mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	S-Protein
protein	O
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
and	O
IL	B-Protein
-	I-Protein
2	E-Protein
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	S-Protein
is	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	S-Protein
(	O
lyt	B-Protein
-	I-Protein
10	E-Protein
)	O
and	O
c	B-Protein
-	I-Protein
Rel	E-Protein
are	O
overexpressed	O
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	S-Protein
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	S-Protein
-	O
dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	S-Protein
(	O
p100	S-Protein
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	S-Protein
(	O
p52	S-Protein
)	O
form	O
,	O
induction	O
of	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-Protein
precursor	E-Protein
is	O
physically	O
associated	O
with	O
c	B-Protein
-	I-Protein
Rel	E-Protein
and	O
with	O
Tax	S-Protein
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	S-Protein
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
NFKB2	S-Protein
alters	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

Autoregulation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transactivator	O
RelA	S-Protein
(	O
p65	S-Protein
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O

RelA	S-Protein
(	O
p65	S-Protein
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50	S-Protein
-	O
p65	S-Protein
NF	O
-	O
kappa	O
B	O
complex	O
and	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
.	O

After	O
cellular	O
activation	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
-	O
induced	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	S-Protein
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	S-Protein
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
but	O
also	O
with	O
other	O
ankyrin	O
motif	O
-	O
rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B2	E-Protein
(	O
p100	S-Protein
)	O
and	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B1	E-Protein
(	O
p105	S-Protein
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	S-Protein
-	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
RelA	S-Protein
-	O
p100	S-Protein
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
activation	O
;	O
(	O
iii	O
)	O
p100	S-Protein
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	S-Protein
-	O
mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	S-Protein
and	O
p100	S-Protein
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	O
localization	O
signal	O
of	O
RelA	S-Protein
,	O
which	O
is	O
required	O
for	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
binding	O
;	O
(	O
v	O
)	O
p100	S-Protein
inhibition	O
of	O
RelA	S-Protein
function	O
requires	O
the	O
C	O
-	O
terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	S-Protein
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	E-Protein
,	O
nuclear	O
RelA	S-Protein
stimulates	O
p100	S-Protein
mRNA	O
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

Calcineurin	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	O
kappa	O
B	O
/	O
MAD3	S-Protein
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O

The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK	O
-	O
506	O
)	O
.	O

Calcineurin	O
,	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
is	O
the	O
FK	O
-	O
506	O
-	O
and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
partially	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
elements	O
IL	O
-	O
2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	S-Protein
and	O
Oct	B-Protein
-	I-Protein
1	E-Protein
)	O
and	O
IL	O
-	O
2E	O
(	O
which	O
binds	O
NF	O
-	O
AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
element	O
.	O

Calcineurin	O
stimulates	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	O
kappa	O
B	O
/	O
MAD3	S-Protein
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK	O
-	O
506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	O
-	O
dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O

Activation	O
of	O
the	O
interleukin	B-Protein
6	E-Protein
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	O
factors	O
NF	B-Protein
-	I-Protein
IL6	E-Protein
and	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	O
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	O
interleukin	B-Protein
6	E-Protein
(	O
IL	B-Protein
-	I-Protein
6	E-Protein
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	O
(	O
LAM	O
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	O
release	O
IL	B-Protein
-	I-Protein
6	E-Protein
in	O
a	O
dose	O
-	O
response	O
manner	O
.	O

LAM	O
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

Both	O
LAM	O
-	O
and	O
LPS	O
-	O
inducible	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-	O
158	O
to	O
-	O
49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-Protein
acetyltransferase	E-Protein
assay	O
.	O

Two	O
nuclear	O
factor	O
NF	B-Protein
-	I-Protein
IL6	E-Protein
(	O
positions	O
-	O
153	O
to	O
-	O
145	O
and	O
-	O
83	O
to	O
-	O
75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
positions	O
-	O
72	O
to	O
-	O
63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
activity	O
by	O
both	O
LAM	O
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF	B-Protein
-	I-Protein
IL6	E-Protein
and	O
NF	O
-	O
kappa	O
B	O
sites	O
mediate	O
IL	B-Protein
-	I-Protein
6	E-Protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	O
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O

Calcineurin	O
activates	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
in	O
synergy	O
with	O
either	O
protein	O
kinase	O
C	O
or	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
in	O
T	O
cells	O
.	O

Two	O
cis	O
-	O
acting	O
elements	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
gene	O
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM	O
-	O
kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
and	O
a	O
PMA	O
/	O
A23187	O
-	O
induced	O
NF	O
-	O
AT	O
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	O
transcription	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
gene	O
.	O

Cotransfection	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	S-Protein
/	O
p65	S-Protein
)	O
-	O
or	O
AP	O
-	O
1	O
(	O
c	B-Protein
-	I-Protein
Jun	E-Protein
/	O
c	B-Protein
-	I-Protein
Fos	E-Protein
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
significantly	O
augmented	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
containing	O
the	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
the	O
CLE0	O
(	O
AP	O
-	O
1	O
/	O
NF	O
-	O
AT	O
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2	B-Protein
+	I-Protein
/	I-Protein
calmodulin	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
phosphatase	E-Protein
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
promoter	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF	O
-	O
kappa	O
B	O
-	O
,	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
AT	O
-	O
binding	O
sequences	O
is	O
required	O
for	O
induction	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
gene	O
through	O
PKC	O
-	O
and	O
Ca2	O
+	O
-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	O
receptor	O
-	O
dependent	O
transcription	O
.	O

Interaction	O
between	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
and	O
glucocorticoid	B-Protein
receptor	E-Protein
(	O
GR	S-Protein
)	O
-	O
mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	O
activating	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	S-Protein
-	O
dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O

TPA	O
-	O
GR	S-Protein
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR	S-Protein
-	O
responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	B-Protein
acetyl	I-Protein
-	I-Protein
transferase	E-Protein
expression	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	S-Protein
DNA	O
-	O
binding	O
domain	O
,	O
whereas	O
amino	O
-	O
or	O
carboxyl	O
-	O
terminal	O
domains	O
were	O
dispensable	O
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	O
.	O

Increased	O
c	B-Protein
-	I-Protein
jun	E-Protein
,	O
jun	B-Protein
-	I-Protein
B	E-Protein
,	O
and	O
jun	B-Protein
-	I-Protein
D	E-Protein
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP	O
-	O
1	O
/	O
TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	B-Protein
acetyl	I-Protein
-	I-Protein
transferase	E-Protein
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

The	O
ability	O
of	O
Jun	O
proteins	O
to	O
cooperate	O
with	O
GR	S-Protein
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c	B-Protein
-	I-Protein
jun	E-Protein
,	O
jun	B-Protein
-	I-Protein
B	E-Protein
,	O
or	O
jun	B-Protein
-	I-Protein
D	E-Protein
expression	O
vectors	O
,	O
which	O
augmented	O
GR	S-Protein
-	O
dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O

Conversely	O
,	O
c	B-Protein
-	I-Protein
jun	E-Protein
and	O
jun	B-Protein
-	I-Protein
B	E-Protein
transfection	O
blunted	O
GR	S-Protein
-	O
dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O

The	O
presence	O
of	O
c	B-Protein
-	I-Protein
fos	E-Protein
had	O
a	O
negative	O
influence	O
on	O
GR	S-Protein
function	O
and	O
correlated	O
with	O
the	O
cell	O
-	O
specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	O
with	O
respect	O
to	O
GR	S-Protein
;	O
high	O
basal	O
expression	O
of	O
c	B-Protein
-	I-Protein
fos	E-Protein
as	O
well	O
as	O
AP	O
-	O
1	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

Furthermore	O
overexpression	O
of	O
exogenous	O
c	B-Protein
-	I-Protein
fos	E-Protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	S-Protein
-	O
dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O

We	O
propose	O
that	O
Jun	O
plays	O
a	O
bifunctional	O
role	O
on	O
GR	S-Protein
-	O
dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell	O
-	O
specific	O
microenvironment	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c	B-Protein
-	I-Protein
fos	E-Protein
appear	O
to	O
be	O
influential	O
.	O

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c	B-Protein
-	I-Protein
jun	E-Protein
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
HL	O
-	O
60	O
cell	O
differentiation	O
.	O

The	O
results	O
demonstrate	O
that	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
,	O
designated	O
HL	O
-	O
60	O
/	O
vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c	B-Protein
-	I-Protein
jun	E-Protein
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
,	O
induces	O
c	B-Protein
-	I-Protein
jun	E-Protein
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c	B-Protein
-	I-Protein
fms	E-Protein
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL	O
-	O
60	O
/	O
vinc	O
revertant	O
(	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	B-Protein
-	I-Protein
jun	E-Protein
expression	O
,	O
suggests	O
that	O
c	B-Protein
-	I-Protein
jun	E-Protein
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	B-Protein
-	I-Protein
B	E-Protein
and	O
fra	B-Protein
-	I-Protein
1	E-Protein
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL	O
-	O
60	O
/	O
vinc	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
,	O
whereas	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
is	O
attenuated	O
in	O
the	O
HL	O
-	O
60	O
/	O
vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL	O
-	O
60	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
.	O

Activity	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	E-Protein
Y	O
-	O
peptide	O
was	O
markedly	O
diminished	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	O
-	O
mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun	O
/	O
fos	O
early	O
response	O
gene	O
expression	O
.	O

Initiation	B-Protein
binding	I-Protein
repressor	E-Protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-Protein
h5	E-Protein
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	B-Protein
binding	I-Protein
repressor	E-Protein
[	O
corrected	O
]	O
(	O
IBR	S-Protein
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-Protein
h5	E-Protein
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	S-Protein
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	S-Protein
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	S-Protein
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	S-Protein
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	S-Protein
and	O
IBF	S-Protein
.	O

IBR	S-Protein
is	O
a	O
503	O
-	O
amino	O
-	O
acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99	O
.	O
0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF	B-Protein
-	I-Protein
1	E-Protein
/	O
alpha	B-Protein
-	I-Protein
Pal	I-Protein
factor	E-Protein
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	S-Protein
and	O
erected	B-Protein
wing	I-Protein
gene	E-Protein
product	O
(	O
EWG	S-Protein
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	S-Protein
and	O
IBF	S-Protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	S-Protein
/	O
F	S-Protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	O
species	O
.	O

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR	S-Protein
/	O
F	S-Protein
harbors	O
the	O
DNA	O
-	O
binding	O
/	O
dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR	S-Protein
/	O
F	S-Protein
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	O
.	O

An	O
inhibitory	O
,	O
"	O
dominant	O
-	O
negative	O
,	O
"	O
form	O
of	O
the	O
calcineurin	B-Protein
catalytic	I-Protein
(	I-Protein
A	I-Protein
)	I-Protein
subunit	E-Protein
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	S-Protein
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B-Protein
(	I-Protein
B	I-Protein
)	I-Protein
subunit	E-Protein
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	O
-	O
dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
"	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
"	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	E-Protein
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B-Protein
B	I-Protein
subunit	E-Protein
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B-Protein
subunit	E-Protein
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
"	O
rescued	O
"	O
by	O
overexpression	O
of	O
transfected	O
B	B-Protein
subunit	E-Protein
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	B-Protein
A	E-Protein
and	O
B	B-Protein
subunits	E-Protein
.	O

Modulation	O
of	O
endogenous	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	E-Protein
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
proportion	O
of	O
HIV	O
-	O
infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
.	O

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
was	O
noted	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
induced	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
and	O
IL	B-Protein
-	I-Protein
6	E-Protein
,	O
but	O
not	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
.	O

IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
(	I-Protein
ra	I-Protein
)	E-Protein
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
-	O
stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	O
IL	O
-	O
1	O
was	O
involved	O
in	O
LPS	O
-	O
mediated	O
viral	O
production	O
.	O

In	O
this	O
regard	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
inhibited	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
-	O
stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up	O
-	O
regulation	O
of	O
endogenous	O
IL	B-Protein
-	I-Protein
1ra	E-Protein
production	O
.	O

Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	O
produced	O
viral	O
inducer	O
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
)	O
and	O
an	O
inhibitor	O
(	O
IL	B-Protein
-	I-Protein
1ra	E-Protein
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
promoter	O
-	O
reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL	B-Protein
-	I-Protein
2	E-Protein
cis	O
-	O
regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	S-Protein
or	O
antibodies	O
to	O
CD3	O
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	O
antibodies	O
or	O
B7	O
-	O
positive	O
(	O
B	O
cells	O
)	O
or	O
B7	O
-	O
negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis	O
-	O
elements	O
.	O

Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
transcriptional	O
regulation	O
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis	O
-	O
elements	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2	B-Protein
+	I-Protein
-	I-Protein
modulating	I-Protein
cyclophilin	I-Protein
ligand	E-Protein
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2	B-Protein
+	I-Protein
-	I-Protein
modulating	I-Protein
cyclophilin	I-Protein
ligand	E-Protein
(	O
CAML	S-Protein
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B-Protein
B	E-Protein
-	O
binding	O
protein	O
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	O
factors	O
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
CAML	S-Protein
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	S-Protein
'	O
s	O
putative	O
membrane	O
-	O
spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	O
C	O
-	O
terminal	O
tail	O
of	O
CAML	S-Protein
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N	O
-	O
terminal	O
hydrophilic	O
domain	O
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	O
protein	O
motif	O
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O

Interactions	O
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	S-Protein
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation	O
-	O
dependent	O
,	O
T	O
cell	O
-	O
specific	O
transacting	O
factors	O
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	S-Protein
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O

Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	B-Protein
I	E-Protein
footprinting	O
indicated	O
that	O
nuclear	O
factors	O
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter	O
-	O
proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter	O
-	O
distal	O
site	O
,	O
META	O
(	O
D	O
+	O
)	O
,	O
within	O
the	O
400	O
-	O
base	O
pair	O
META	O
region	O
.	O

Nuclear	O
factors	O
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D	O
-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D	O
+	O
)	O
.	O

META	O
(	O
D	O
+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA	O
-	O
sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
targets	O
did	O
not	O
compete	O
for	O
the	O
META	O
(	O
D	O
+	O
)	O
binding	O
factor	O
(	O
s	O
)	O
.	O

The	O
SV40	S-Protein
core	O
sequence	O
competed	O
for	O
META	O
(	O
D	O
+	O
)	O
binding	O
factors	O
,	O
but	O
META	O
(	O
D	O
+	O
)	O
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	S-Protein
probe	O
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D	O
+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell	O
-	O
type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	O
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Monocytic	O
cell	O
type	O
-	O
specific	O
transcriptional	O
induction	O
of	O
collagenase	O
.	O

Interstitial	O
collagenase	O
(	O
MMP	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
a	O
metalloproteinase	O
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	O
I	O
collagen	O
fibrils	O
.	O

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	O
collagen	O
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	O
expression	O
is	O
cell	O
-	O
type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	O
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	O
alter	O
fibroblast	O
collagenase	O
expression	O
.	O

Since	O
promoter	O
elements	O
controlling	O
collagenase	O
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS	O
-	O
or	O
zymosan	O
-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A	O
-	O
binding	O
protein	O
-	O
3	O
site	O
(	O
-	O
83	O
to	O
-	O
91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-	O
102	O
to	O
-	O
105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O

Mutagenesis	O
of	O
the	O
activator	O
protein	O
-	O
1	O
[	O
AP	O
-	O
1	O
]	O
site	O
at	O
-	O
72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS	O
/	O
zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
like	O
site	O
at	O
-	O
20	O
to	O
-	O
10	O
had	O
no	O
effect	O
.	O

Nuclear	O
extracts	O
from	O
LPS	O
-	O
and	O
zymosan	O
-	O
treated	O
cells	O
showed	O
strong	O
AP	O
-	O
1	O
activity	O
by	O
gel	O
-	O
shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP	O
-	O
1	O
complexes	O
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP	O
-	O
1	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	O
transcription	O
in	O
macrophagelike	O
cells	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	O
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

(	O
2E	O
)	O
-	O
3	O
-	O
[	O
5	O
-	O
(	O
2	O
,	O
3	O
-	O
Dimethoxy	O
-	O
6	O
-	O
methyl	O
-	O
1	O
,	O
4	O
-	O
benzoquinoyl	O
)	O
]	O
-	O
2	O
-	O
nonyl	O
-	O
2	O
-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
gene	O
and	O
on	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF	O
-	O
alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted	O
-	O
type	O
placental	B-Protein
alkaline	I-Protein
phosphatase	E-Protein
(	O
PLAP	S-Protein
)	O
reporter	O
gene	O
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1	O
.	O
4	O
-	O
kb	O
human	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
promoter	O
.	O

A	O
stable	O
transformant	O
of	O
the	O
PLAP	S-Protein
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	S-Protein
activity	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B	O
-	O
1	O
,	O
kappa	O
B	O
-	O
2	O
,	O
kappa	O
B	O
-	O
3	O
,	O
kappa	O
B	O
-	O
4	O
)	O
in	O
human	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
promoter	O
.	O

By	O
using	O
mutated	O
promoter	O
-	O
PLAP	S-Protein
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF	O
-	O
kappa	O
B	O
sites	O
were	O
necessary	O
for	O
induction	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double	O
-	O
stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF	O
-	O
kappa	O
B	O
consisting	O
of	O
p50	S-Protein
/	O
p65	S-Protein
heterodimer	O
bound	O
to	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
recognition	O
sites	O
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
expression	O
.	O

E3330	O
decreased	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
/	O
or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Western	O
blotting	O
analysis	O
with	O
anti	O
-	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	E-Protein
antibody	O
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	E-Protein
,	O
which	O
is	O
an	O
inhibitory	O
protein	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
role	O
of	O
p16	S-Protein
in	O
the	O
E2F	O
-	O
dependent	O
thymidine	B-Protein
kinase	E-Protein
regulation	O
.	O

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	S-Protein
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	S-Protein
,	O
the	O
inhibitor	O
of	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
-	I-Protein
kinase	I-Protein
-	I-Protein
4	E-Protein
and	O
6	S-Protein
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B-Protein
protein	E-Protein
by	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
kinases	I-Protein
4	E-Protein
and	O
6	S-Protein
prevents	O
its	O
interaction	O
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	B-Protein
kinase	E-Protein
.	O

Although	O
a	O
role	O
of	O
p16	S-Protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	O
-	O
mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-Protein
kinase	E-Protein
in	O
phytohemagglutinin	S-Protein
-	O
stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16	S-Protein
-	O
negative	O
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
.	O

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B-Protein
kinase	E-Protein
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	B-Protein
kinase	E-Protein
mRNA	O
expression	O
.	O

Transient	O
expression	O
of	O
p16	S-Protein
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B-Protein
protein	E-Protein
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	O
of	O
p16	S-Protein
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	B-Protein
kinase	E-Protein
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	B-Protein
protein	E-Protein
and	O
decrease	O
of	O
free	O
E2F	O
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	B-Protein
kinase	E-Protein
promoter	O
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	S-Protein
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	B-Protein
protein	E-Protein
.	O

Rel	S-Protein
-	O
deficient	O
T	O
cells	O
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B-Protein
3	E-Protein
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
.	O

The	O
c	B-Protein
-	I-Protein
rel	E-Protein
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
family	O
of	O
transcription	O
factors	O
.	O

Mice	O
lacking	O
Rel	S-Protein
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	S-Protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	O
surface	O
activation	O
markers	O
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel	S-Protein
-	O
/	O
-	O
T	O
cells	O
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
)	I-Protein
chain	E-Protein
(	O
CD25	S-Protein
)	O
,	O
CD69	S-Protein
and	O
L	B-Protein
-	I-Protein
selectin	E-Protein
(	O
CD62	S-Protein
)	O
is	O
normal	O
in	O
mitogen	O
-	O
activated	O
Rel	S-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
but	O
cytokine	O
production	O
is	O
impaired	O
.	O

In	O
Rel	S-Protein
-	O
/	O
-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
3	E-Protein
,	O
IL	B-Protein
-	I-Protein
5	E-Protein
,	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	E-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
)	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
,	O
and	O
gamma	B-Protein
interferon	E-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
)	O
were	O
only	O
2	O
-	O
to	O
3	O
-	O
fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	S-Protein
stimulated	O
Rel	S-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	O
.	O

Exogenous	O
IL	B-Protein
-	I-Protein
2	E-Protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti	O
-	O
CD3	O
-	O
and	O
anti	O
-	O
CD28	S-Protein
-	O
treated	O
Rel	O
-	O
/	O
-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL	B-Protein
-	I-Protein
5	E-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
3	E-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen	O
-	O
activated	O
Rel	S-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
lipopolysaccharide	O
-	O
stimulated	O
Rel	S-Protein
-	O
/	O
-	O
macrophages	O
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
.	O

These	O
findings	O
establish	O
that	O
Rel	S-Protein
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
3	E-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	E-Protein
.	O

Human	O
T	O
lymphotropic	O
virus	O
-	O
I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	O
expression	O
of	O
the	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
,	O
galectin	B-Protein
-	I-Protein
3	E-Protein
.	O

Animal	O
lectins	O
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin	B-Protein
-	I-Protein
3	E-Protein
is	O
a	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
previously	O
designated	O
as	O
epsilon	B-Protein
BP	E-Protein
(	O
IgE	B-Protein
-	I-Protein
binding	I-Protein
protein	E-Protein
)	O
,	O
CBP35	S-Protein
,	O
Mac	B-Protein
-	I-Protein
2	E-Protein
,	O
L	B-Protein
-	I-Protein
29	E-Protein
,	O
and	O
L	B-Protein
-	I-Protein
34	E-Protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

Galectin	B-Protein
-	I-Protein
3	E-Protein
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	O
,	O
with	O
the	O
notable	O
exception	O
of	O
B	O
and	O
T	O
lymphocytes	O
.	O

We	O
now	O
report	O
that	O
galectin	B-Protein
-	I-Protein
3	E-Protein
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-	O
I	O
-	O
infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6T	O
,	O
HUT	O
102	O
,	O
K3T	O
,	O
MT	O
-	O
2	O
,	O
and	O
SLB	O
-	O
I	O
,	O
but	O
is	O
not	O
expressed	O
in	O
non	O
-	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
cell	O
lines	O
such	O
as	O
Jurkat	O
,	O
CEM	O
,	O
and	O
MOLT	O
-	O
4	O
.	O

In	O
addition	O
,	O
the	O
galectin	B-Protein
-	I-Protein
3	E-Protein
level	O
was	O
markedly	O
increased	O
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV	O
-	O
I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O

The	O
up	O
-	O
regulation	O
of	O
galectin	B-Protein
-	I-Protein
3	E-Protein
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin	B-Protein
-	I-Protein
3	E-Protein
were	O
found	O
in	O
the	O
S1T	O
and	O
ATL	O
-	O
1K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV	O
-	O
I	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
the	O
galectin	B-Protein
-	I-Protein
3	E-Protein
promoter	O
was	O
significantly	O
up	O
-	O
regulated	O
by	O
expression	O
vectors	O
encoding	O
the	O
40	O
-	O
kd	O
Tax	S-Protein
protein	O
,	O
a	O
potent	O
transactivator	O
in	O
HTLV	O
-	O
I	O
.	O

Analysis	O
of	O
various	O
Tax	S-Protein
mutants	O
suggested	O
that	O
galectin	B-Protein
-	I-Protein
3	E-Protein
promoter	O
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic	O
-	O
AMP	O
-	O
responsive	O
element	O
binding	O
protein	O
/	O
activation	O
transcription	O
factor	O
family	O
of	O
transcription	O
factors	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
induction	O
.	O

Transfection	O
of	O
human	O
promonocytic	O
U	O
-	O
937	O
cells	O
with	O
an	O
HTLV	O
-	O
I	O
Tax	S-Protein
expression	O
vector	O
induced	O
galectin	B-Protein
-	I-Protein
3	E-Protein
expression	O
in	O
this	O
cell	O
line	O
.	O

Functionally	O
,	O
galectin	B-Protein
-	I-Protein
3	E-Protein
was	O
shown	O
to	O
activate	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
production	O
in	O
Jurkat	O
T	O
cells	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV	O
-	O
I	O
Tax	S-Protein
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin	B-Protein
-	I-Protein
3	E-Protein
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV	O
-	O
I	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	S-Protein
response	O
element	O
within	O
the	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
enhancer	O
correlates	O
with	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
production	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
molecules	O
such	O
as	O
CD28	S-Protein
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
produce	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL	B-Protein
-	I-Protein
2	E-Protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	S-Protein
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	O
factor	O
of	O
mitogenic	O
-	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
MATp35	O
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
.	O

Induction	O
of	O
NF	O
-	O
MATp35	O
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	S-Protein
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF	O
-	O
MATp35	O
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	O
-	O
MATp35	O
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF	O
-	O
MATp35	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
MATp35	O
shows	O
excellent	O
correlation	O
with	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
expression	O
.	O

Preassociation	O
of	O
STAT1	S-Protein
with	O
STAT2	S-Protein
and	O
STAT3	S-Protein
in	O
separate	O
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	S-Protein
or	O
STAT2	S-Protein
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	O
protein	O
.	O

Similarly	O
,	O
STAT1	S-Protein
-	O
STAT3	S-Protein
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O

STAT1	S-Protein
and	O
STAT2	S-Protein
or	O
STAT1	S-Protein
and	O
STAT3	S-Protein
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	S-Protein
-	O
STAT2	S-Protein
signaling	O
complex	O
.	O

Newly	O
translated	O
STAT1	S-Protein
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	S-Protein
and	O
STAT3	S-Protein
,	O
but	O
we	O
show	O
that	O
STAT2	S-Protein
and	O
STAT3	S-Protein
exist	O
in	O
separate	O
heterocomplexes	O
with	O
STAT1	S-Protein
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	S-Protein
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Inhibition	O
of	O
p105	S-Protein
processing	O
by	O
NF	O
-	O
kappaB	O
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
involves	O
proteasome	O
-	O
mediated	O
processing	O
of	O
the	O
NF	B-Protein
-	I-Protein
kappaB1	E-Protein
p105	S-Protein
precursor	O
protein	O
,	O
which	O
generates	O
the	O
p50	S-Protein
subunit	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
processing	O
of	O
p105	S-Protein
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	S-Protein
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	S-Protein
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	S-Protein
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	S-Protein
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	S-Protein
or	O
other	O
NF	O
-	O
kappaB	O
subunits	O
,	O
including	O
RelA	S-Protein
and	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
that	O
physically	O
interact	O
with	O
p105	S-Protein
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	S-Protein
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	O
-	O
kappaB	O
subunits	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	S-Protein
undergoes	O
degradation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	S-Protein
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	S-Protein
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	S-Protein
are	O
differentially	O
regulated	O
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
of	O
the	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O

To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	S-Protein
or	O
the	O
adult	B-Protein
globin	E-Protein
developmental	O
program	O
.	O

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	O
-	O
E2	O
(	O
or	O
AP	O
-	O
1	O
)	O
and	O
GATA	B-Protein
-	I-Protein
1	E-Protein
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	S-Protein
or	O
the	O
adult	B-Protein
globin	I-Protein
genes	E-Protein
are	O
expressed	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	S-Protein
or	O
the	O
adult	B-Protein
globin	E-Protein
program	O
.	O

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma	B-Protein
-	E-Protein
and	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta	B-Protein
-	I-Protein
globin	E-Protein
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma	B-Protein
-	E-Protein
and	O
beta	B-Protein
-	I-Protein
globin	E-Protein
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	S-Protein
or	O
the	O
adult	B-Protein
globin	E-Protein
gene	O
.	O

Interleukin	B-Protein
10	E-Protein
induced	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	O
protein	O
kinases	O
.	O

IL	B-Protein
-	I-Protein
10	E-Protein
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
on	O
the	O
expression	O
of	O
the	O
protooncogene	O
c	B-Protein
-	I-Protein
fos	E-Protein
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	O
CD20	S-Protein
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL	B-Protein
-	I-Protein
10	E-Protein
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

RNA	O
was	O
extracted	O
by	O
phenol	O
/	O
chloroform	O
and	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2	O
-	O
4	O
fold	O
increase	O
of	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
10	E-Protein
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
2	O
hrs	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
declined	O
to	O
basal	O
levels	O
.	O

The	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
was	O
dose	O
-	O
dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng	O
/	O
ml	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
.	O

The	O
IL	B-Protein
-	I-Protein
10	E-Protein
effect	O
on	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
induced	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
was	O
observed	O
.	O

In	O
addition	O
,	O
H	O
-	O
7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
kinases	O
,	O
significantly	O
blocked	O
IL	B-Protein
-	I-Protein
10	E-Protein
mediated	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL	B-Protein
-	I-Protein
10	E-Protein
induces	O
c	B-Protein
-	I-Protein
fos	E-Protein
expression	O
in	O
human	O
B	O
-	O
cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine	O
/	O
threonine	O
kinases	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL	B-Protein
-	I-Protein
10	E-Protein
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL	B-Protein
-	I-Protein
10	E-Protein
stimulates	O
human	O
B	O
-	O
cells	O
.	O

IL	B-Protein
-	I-Protein
10	E-Protein
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O

IL	B-Protein
-	I-Protein
10	E-Protein
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	O
-	O
CD3	O
mAb	O
OKT3	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	O
-	O
protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
protein	O
family	O
,	O
the	O
p50	S-Protein
/	O
p65	S-Protein
(	O
Rel	B-Protein
A	E-Protein
)	O
heterodimeric	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL	B-Protein
-	I-Protein
10	E-Protein
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O

IL	B-Protein
-	I-Protein
10	E-Protein
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL	B-Protein
-	I-Protein
10	E-Protein
are	O
able	O
so	O
inhibit	O
NF	O
-	O
kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
up	O
-	O
regulation	O
of	O
CD80	B-Protein
Ag	E-Protein
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	O
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL	B-Protein
-	I-Protein
10	E-Protein
,	O
and	O
the	O
anti	O
-	O
CD28	S-Protein
mAb	O
CLB	O
-	O
CD28	O
/	O
1	O
restores	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
IL	B-Protein
-	I-Protein
10	E-Protein
-	O
inhibited	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	O
-	O
regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	S-Protein
,	O
produced	O
by	O
IL	B-Protein
-	I-Protein
10	E-Protein
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL	B-Protein
-	I-Protein
10	E-Protein
can	O
inhibit	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Vitamin	O
D3	O
-	O
and	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	O
vitamin	B-Protein
D3	I-Protein
receptor	E-Protein
,	O
retinoic	O
acid	O
receptors	O
,	O
and	O
retinoid	O
X	O
receptors	O
in	O
U	O
-	O
937	O
cells	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	O
and	O
VitD3	O
receptor	O
network	O
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-	O
and	O
VitD3	O
-	O
signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
RA	O
and	O
VitD3	O
receptors	O
[	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
,	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
and	O
VitD3	B-Protein
receptor	E-Protein
(	O
VDR	S-Protein
)	O
]	O
in	O
the	O
U	O
-	O
937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR	S-Protein
/	O
RXR	O
DNA	O
-	O
binding	O
complexes	O
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element	O
-	O
driven	O
reporter	O
construct	O
.	O

Several	O
DNA	O
-	O
binding	O
complexes	O
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O

Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B-Protein
beta	E-Protein
/	O
RXR	O
DNA	O
binding	O
,	O
activated	O
RARE	O
-	O
dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR	B-Protein
-	I-Protein
beta	E-Protein
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA	O
-	O
stimulated	O
formation	O
of	O
RAR	B-Protein
beta	E-Protein
/	O
RXR	O
heterodimers	O
,	O
favoring	O
VDR	S-Protein
/	O
RXR	O
binding	O
to	O
the	O
RARE	O
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	S-Protein
and	O
CD49f	S-Protein
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U	O
-	O
937	O
cell	O
differentiation	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA	O
-	O
stimulated	O
,	O
RARE	O
-	O
mediated	O
transcription	O
nor	O
the	O
induced	O
RAR	B-Protein
-	I-Protein
beta	E-Protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid	O
-	O
induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	O
-	O
mediated	O
signal	O
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation	O
-	O
inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

Calcium	O
-	O
dependent	O
immediate	O
-	O
early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha	B-Protein
-	I-Protein
ras	E-Protein
.	O

The	O
induction	O
of	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr	B-Protein
-	I-Protein
1	E-Protein
,	O
c	B-Protein
-	I-Protein
fos	E-Protein
,	O
and	O
c	B-Protein
-	I-Protein
jun	E-Protein
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	O
kinases	O
.	O

p21	B-Protein
(	I-Protein
ras	I-Protein
)	E-Protein
,	O
a	O
guanine	O
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T	O
-	O
cell	O
signal	O
transduction	O
through	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
.	O

The	O
involvement	O
of	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	E-Protein
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	O
-	O
AT	O
.	O

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	E-Protein
)	O
and	O
their	O
correlated	O
consequences	O
.	O

The	O
expression	O
of	O
activated	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	E-Protein
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O

This	O
inhibition	O
of	O
calcium	O
-	O
activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	O
in	O
this	O
regulation	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B-Protein
(	I-Protein
ras	E-Protein
)	O
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
expression	O
and	O
protein	O
production	O
.	O

These	O
results	O
suggest	O
that	O
p2l	B-Protein
(	I-Protein
ras	I-Protein
)	E-Protein
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid	O
-	O
and	O
Fas	S-Protein
-	O
mediated	O
cytotoxicity	O
.	O

Fas	S-Protein
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

Restimulation	O
of	O
T	O
cell	O
blasts	O
up	O
-	O
regulates	O
Fas	S-Protein
and	O
Fas	B-Protein
ligand	E-Protein
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	S-Protein
-	O
mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
,	O
whereas	O
etoposide	O
-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl	B-Protein
-	I-Protein
xL	E-Protein
and	O
adenovirus	O
E1B	B-Protein
19K	E-Protein
did	O
not	O
interfere	O
with	O
anti	O
-	O
Fas	S-Protein
killing	O
.	O

In	O
contrast	O
,	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
and	O
interleukin	B-Protein
-	I-Protein
1beta	E-Protein
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	O
cells	O
normally	O
express	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
and	O
Bcl	B-Protein
-	I-Protein
xL	E-Protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	S-Protein
-	O
mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Interferons	O
induce	O
normal	O
and	O
aberrant	O
retinoic	B-Protein
-	I-Protein
acid	I-Protein
receptors	I-Protein
type	I-Protein
alpha	E-Protein
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	O
markers	O
.	O

Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	B-Protein
-	I-Protein
acid	I-Protein
receptor	I-Protein
type	I-Protein
alpha	E-Protein
(	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	E-Protein
)	O
and	O
the	O
leukemia	B-Protein
-	I-Protein
specific	I-Protein
retinoic	I-Protein
acid	I-Protein
receptor	E-Protein
PML	B-Protein
-	I-Protein
RAR	E-Protein
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	E-Protein
and	O
PML	B-Protein
-	I-Protein
RAR	E-Protein
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Up	O
-	O
regulation	O
of	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	E-Protein
and	O
PML	B-Protein
-	I-Protein
RAR	E-Protein
gene	O
expression	O
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
,	O
i	O
.	O
e	O
.	O
,	O
granulocyte	B-Protein
-	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
receptor	E-Protein
mRNA	O
and	O
leukocyte	B-Protein
alkaline	I-Protein
phosphatase	E-Protein
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	O
of	O
the	O
myeloid	O
surface	O
markers	O
CD11b	S-Protein
and	O
CD33	S-Protein
.	O

The	O
IFN	O
-	O
dependent	O
increase	O
in	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	E-Protein
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	B-Protein
-	I-Protein
RAR	E-Protein
positive	O
cells	O
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

An	O
IL	B-Protein
-	I-Protein
2	E-Protein
response	O
element	O
in	O
the	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	E-Protein
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	O
Stat5	S-Protein
,	O
Elf	B-Protein
-	I-Protein
1	E-Protein
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
(	I-Protein
Y	I-Protein
)	E-Protein
and	O
a	O
GATA	O
family	O
protein	O
.	O

Expression	O
of	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2	I-Protein
)	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	E-Protein
gene	O
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL	B-Protein
-	I-Protein
2	E-Protein
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL	B-Protein
-	I-Protein
2	E-Protein
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non	O
-	O
consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non	O
-	O
consensus	O
GAS	O
motif	O
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL	B-Protein
-	I-Protein
2	E-Protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL	B-Protein
-	I-Protein
2	E-Protein
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

Multiple	O
factors	O
including	O
Stat5	S-Protein
,	O
Elf	B-Protein
-	I-Protein
1	E-Protein
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
(	I-Protein
Y	I-Protein
)	E-Protein
and	O
GATA	O
family	O
proteins	O
bind	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	O
family	O
protein	O
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
promoter	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
2	E-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	E-Protein
promoter	O
activity	O
requires	O
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	O
and	O
negative	O
regulatory	O
factors	O
.	O

Active	O
suppression	O
of	O
the	O
class	B-Protein
II	I-Protein
transactivator	E-Protein
-	O
encoding	O
AIR	O
-	O
1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
expression	O
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O

Class	O
II	O
molecules	O
are	O
not	O
expressed	O
in	O
plasma	O
cells	O
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell	O
-	O
specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	B-Protein
II	I-Protein
transactivator	E-Protein
(	O
CIITA	S-Protein
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR	O
-	O
1	O
locus	O
derived	O
from	O
CIITA	S-Protein
-	O
expressing	O
cells	O
do	O
not	O
express	O
CIITA	S-Protein
-	O
specific	O
transcripts	O
.	O

Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	S-Protein
coding	O
sequence	O
under	O
the	O
control	O
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
product	O
across	O
species	O
barriers	O
.	O

Interestingly	O
,	O
in	O
CIITA	S-Protein
-	O
transfected	O
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
heterodimer	O
was	O
not	O
observed	O
.	O

This	O
result	O
was	O
not	O
attributable	O
to	O
lack	O
of	O
HLA	B-Protein
-	I-Protein
DQ	I-Protein
alpha	E-Protein
or	O
-	B-Protein
DQ	I-Protein
beta	E-Protein
transcription	O
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA	S-Protein
-	O
transfected	O
hybrids	O
,	O
although	O
at	O
reduced	O
levels	O
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	S-Protein
-	O
independent	O
mechanism	O
.	O

Silencing	O
of	O
human	O
fetal	B-Protein
globin	E-Protein
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	O
beta	O
-	O
globin	O
gene	O
activator	O
protein	O
EKLF	S-Protein
.	O

Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O

A	O
switch	O
from	O
human	B-Protein
fetal	I-Protein
(	I-Protein
gamma	I-Protein
)	I-Protein
-	E-Protein
to	O
adult	B-Protein
(	I-Protein
beta	I-Protein
)	I-Protein
-	I-Protein
globin	E-Protein
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	B-Protein
Kruppel	I-Protein
-	I-Protein
like	I-Protein
factor	E-Protein
(	O
EKLF	S-Protein
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O

To	O
examine	O
the	O
role	O
of	O
EKLF	S-Protein
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma	B-Protein
-	I-Protein
globin	E-Protein
gene	O
we	O
interbred	O
EKLF	S-Protein
heterozygotes	O
(	O
+	O
/	O
-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
yeast	O
artificial	O
chromosome	O
transgene	O
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	S-Protein
,	O
while	O
human	O
beta	B-Protein
-	I-Protein
globin	E-Protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma	B-Protein
-	I-Protein
globin	E-Protein
transcripts	O
are	O
elevated	O
approximately	O
5	O
-	O
fold	O
.	O

Impaired	O
silencing	O
of	O
gamma	B-Protein
-	I-Protein
globin	E-Protein
expression	O
identifies	O
EKLF	S-Protein
as	O
the	O
first	O
transcription	O
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma	B-Protein
-	I-Protein
globin	E-Protein
to	O
beta	B-Protein
-	I-Protein
globin	E-Protein
switch	O
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	S-Protein
mediates	O
an	O
adult	O
stage	O
-	O
specific	O
interaction	O
between	O
the	O
beta	B-Protein
-	I-Protein
globin	E-Protein
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma	B-Protein
-	I-Protein
globin	E-Protein
gene	O
.	O

Nasal	O
NK	O
-	O
and	O
T	O
-	O
cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
.	O

Nasal	O
T	O
/	O
NK	O
-	O
cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T	O
-	O
cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Both	O
NK	O
-	O
and	O
T	O
-	O
cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK	O
-	O
cell	O
and	O
4	O
as	O
T	O
-	O
cell	O
tumours	O
.	O

ISH	O
for	O
EBV	O
-	O
encoded	O
small	O
non	O
-	O
polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O

RT	O
-	O
PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	O
EBNAI	S-Protein
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	O
membrane	O
proteins	O
,	O
LMP1	S-Protein
and	O
2	S-Protein
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	S-Protein
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1	S-Protein
+	O
and	O
LMP1	S-Protein
-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

Although	O
2	O
early	O
lytic	O
transcripts	O
,	O
BZLF1	S-Protein
and	O
BHRF1	S-Protein
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	O
of	O
ZEBRA	S-Protein
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	O
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

Down	O
-	O
regulation	O
of	O
immunogenic	O
proteins	O
(	O
EBNA2	S-Protein
-	O
EBNA6	S-Protein
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T	O
-	O
cell	O
surveillance	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140	O
-	O
kDa	O
protein	O
designated	O
Sp140	S-Protein
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Sp140	S-Protein
was	O
similar	O
to	O
Sp100	S-Protein
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O

The	O
carboxyl	O
portion	O
of	O
Sp140	S-Protein
contained	O
a	O
zinc	O
-	O
finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	S-Protein
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	S-Protein
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	S-Protein
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O

The	O
location	O
of	O
Sp140	S-Protein
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	S-Protein
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20	O
-	O
methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
'	O
s	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20	O
-	O
epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon	O
-	O
20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20	O
-	O
methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20	O
-	O
methyl	O
-	O
and	O
20	O
-	O
methyl	O
-	O
23	O
-	O
eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Both	O
compounds	O
show	O
about	O
2	O
-	O
fold	O
lower	O
affinity	O
to	O
the	O
VD	B-Protein
receptor	E-Protein
(	O
VDR	S-Protein
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30	O
-	O
fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300	O
-	O
fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF	O
-	O
7	O
cells	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10	O
-	O
fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium	O
-	O
mobilizing	O
potency	O
as	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	O
element	O
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	O
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	B-Protein
receptor	E-Protein
(	O
AR	S-Protein
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-	O
508	O
to	O
-	O
501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
AR	S-Protein
mRNA	O
was	O
upregulated	O
in	O
LNCaP	O
but	O
not	O
in	O
either	O
PC	O
-	O
3	O
or	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B-Protein
binding	I-Protein
protein	E-Protein
(	O
CREB	S-Protein
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	S-Protein
-	O
CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	S-Protein
.	O

The	O
ability	O
to	O
regulate	O
AR	S-Protein
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
human	O
cells	O
.	O

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O

Treatment	O
of	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
(	O
the	O
heterodimer	O
p50	S-Protein
/	O
p65	S-Protein
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O

Western	O
blot	O
analysis	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
subunits	O
(	O
IkappaB	O
)	O
demonstrated	O
that	O
both	O
IkappaB	B-Protein
-	I-Protein
alpha	E-Protein
proteolysis	O
and	O
p105	S-Protein
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p	O
-	O
bromophenacyl	O
-	O
bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF	O
-	O
kappaB	O
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O

Moreover	O
,	O
ACH	O
-	O
2	O
cells	O
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
in	O
the	O
supernatants	O
.	O

The	O
importance	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
release	O
in	O
NF	O
-	O
kappaB	O
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappaB	O
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
and	O
HOCl	O
was	O
detected	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	O
-	O
kappaB	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
release	O
.	O

Thymocytes	O
control	O
the	O
CD4	S-Protein
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O

We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	S-Protein
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	O
the	O
CD4	S-Protein
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

The	O
5	O
'	O
-	O
positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4	S-Protein
-	O
CD8	O
-	O
double	O
-	O
negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double	O
-	O
positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4	O
+	O
CD8int	O
/	O
-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	S-Protein
gene	O
,	O
is	O
required	O
for	O
CD4	S-Protein
gene	O
expression	O
in	O
this	O
population	O
.	O

The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	S-Protein
silencer	O
which	O
inhibits	O
CD4	S-Protein
gene	O
expression	O
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down	O
-	O
regulate	O
CD4	S-Protein
gene	O
expression	O
.	O

Unexpectedly	O
,	O
the	O
CD4	S-Protein
silencer	O
is	O
also	O
active	O
in	O
CD4	S-Protein
+	O
CD8int	O
/	O
-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti	O
-	O
silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	S-Protein
expression	O
in	O
this	O
cell	O
population	O
.	O

Altogether	O
,	O
the	O
CD4	S-Protein
gene	O
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

Triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
differentially	O
modulates	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti	O
-	O
HLA	O
-	O
DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm	O
-	O
6	O
and	O
BV173	O
.	O

TNF	B-Protein
-	I-Protein
alpha	E-Protein
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O

Secreted	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
-	O
neutralizing	O
antibodies	O
did	O
not	O
upregulate	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

In	O
contrast	O
,	O
released	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
Sc	O
-	O
I	O
,	O
and	O
Raji	O
cells	O
induced	O
by	O
mAb	O
L243	O
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	O
surface	O
HLA	O
-	O
DR	O
antigens	O
;	O
(	O
c	O
)	O
secreted	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	O
interleukin	B-Protein
-	I-Protein
6	E-Protein
gene	O
expression	O
.	O

BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O

Interleukin	B-Protein
-	I-Protein
6	E-Protein
(	O
IL	B-Protein
-	I-Protein
6	E-Protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin	B-Protein
-	I-Protein
6	E-Protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

The	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	O
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL	B-Protein
-	I-Protein
6	E-Protein
production	O
.	O

METHODS	O
:	O
THP	O
-	O
1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O

Interleukin	B-Protein
-	I-Protein
6	E-Protein
protein	O
and	O
IL	B-Protein
-	I-Protein
6	E-Protein
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O

Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL	B-Protein
-	I-Protein
6	E-Protein
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	E-Protein
(	O
CAT	S-Protein
)	O
or	O
IL	B-Protein
-	I-Protein
6	E-Protein
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
activity	O
.	O

RESULTS	O
:	O
Interleukin	B-Protein
-	I-Protein
6	E-Protein
protein	O
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS	O
-	O
stimulated	O
control	O
cells	O
.	O

Cytomegalovirus	O
IE	O
gene	O
products	O
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
activity	O
in	O
both	O
IL	B-Protein
-	I-Protein
6	E-Protein
CAT	S-Protein
and	O
IL	B-Protein
-	I-Protein
6	E-Protein
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL	B-Protein
-	I-Protein
6	E-Protein
luciferase	O
activity	O
in	O
LPS	O
-	O
stimulated	O
CMV	O
transfected	O
cells	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	O
immediate	O
early	O
gene	O
products	O
significantly	O
enhanced	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	E-Protein
in	O
LPS	O
-	O
stimulated	O
cells	O
.	O

The	O
increase	O
in	O
IL	B-Protein
-	I-Protein
6	E-Protein
luciferase	O
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	E-Protein
promoter	O
responsive	O
to	O
IL	O
-	O
1	O
,	O
TNF	B-Protein
alpha	E-Protein
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

The	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
enhance	O
IL	B-Protein
-	I-Protein
6	E-Protein
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O

Homodimerization	O
of	O
the	O
human	O
interleukin	B-Protein
4	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	E-Protein
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
gamma	I-Protein
chain	E-Protein
.	O

The	O
cytokines	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	E-Protein
and	O
IL	B-Protein
-	I-Protein
13	E-Protein
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL	B-Protein
-	I-Protein
4	E-Protein
-	O
binding	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	E-Protein
,	O
which	O
is	O
shared	O
with	O
the	O
IL	O
-	O
13R	O
,	O
and	O
the	O
IL	B-Protein
-	I-Protein
2Rgamma	I-Protein
(	I-Protein
gammac	I-Protein
)	I-Protein
chain	E-Protein
,	O
which	O
is	O
shared	O
with	O
IL	B-Protein
-	I-Protein
7R	E-Protein
,	O
IL	B-Protein
-	I-Protein
9R	E-Protein
,	O
and	O
IL	O
-	O
15R	O
.	O

IL	B-Protein
-	I-Protein
4	E-Protein
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	B-Protein
chain	E-Protein
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL	B-Protein
-	I-Protein
4	E-Protein
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	B-Protein
chain	E-Protein
may	O
involve	O
signaling	O
via	O
the	O
IL	O
-	O
13R	O
.	O

Alternatively	O
,	O
the	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	E-Protein
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	S-Protein
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL	B-Protein
-	I-Protein
4Ralpha	E-Protein
induces	O
Janus	B-Protein
kinase	I-Protein
1	E-Protein
(	O
Jak1	S-Protein
)	O
activation	O
,	O
STAT6	S-Protein
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1	S-Protein
-	O
binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL	B-Protein
-	I-Protein
4Ralpha	E-Protein
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	B-Protein
CD8alpha	I-Protein
/	I-Protein
IL	I-Protein
-	I-Protein
4Ralpha	I-Protein
receptor	E-Protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	E-Protein
is	O
sufficient	O
to	O
transduce	O
Jak1	S-Protein
-	O
dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	O
-	O
I	O
Tax	S-Protein
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Tax1	S-Protein
,	O
a	O
transcriptional	O
trans	O
-	O
activator	O
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB	O
/	O
ATF	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
SRF	S-Protein
.	O

This	O
Tax1	S-Protein
-	O
induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	S-Protein
-	O
inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	S-Protein
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	E-Protein
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4	S-Protein
+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
SRF	S-Protein
pathways	O
is	O
also	O
required	O
.	O

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	B-Protein
receptor	E-Protein
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	B-Protein
receptor	E-Protein
(	O
hMR	S-Protein
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729	O
-	O
Lys984	O
of	O
hMR	S-Protein
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	S-Protein
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	S-Protein
form	O
and	O
the	O
transformed	O
MR	S-Protein
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	S-Protein
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	S-Protein
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	S-Protein
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	S-Protein
complex	O
and	O
the	O
antibody	O
-	O
MR	S-Protein
complex	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	S-Protein
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	S-Protein
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729	O
-	O
Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J	O
.	O
Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol	O
.	O
57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729	O
-	O
Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	B-Protein
alpha	E-Protein
.	O

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	B-Protein
alpha	E-Protein
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	O
-	O
positive	O
cells	O
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-	O
gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-Protein
deltaepsilongamma	E-Protein
and	O
TCR	B-Protein
zeta	E-Protein
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	B-Protein
zeta	I-Protein
chain	E-Protein
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	B-Protein
kinase	I-Protein
p56	I-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	O
of	O
p65	S-Protein
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta	O
-	O
chain	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-Protein
zeta	I-Protein
chain	E-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	O
-	O
chain	O
.	O

An	O
isotype	O
-	O
specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	B-Protein
II	I-Protein
transactivator	E-Protein
.	O

Patients	O
with	O
one	O
type	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-Protein
II	I-Protein
transactivator	E-Protein
(	O
CIITA	S-Protein
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA	O
-	O
DR	O
,	O
-	O
DQ	O
,	O
and	O
-	O
DP	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DP	O
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	S-Protein
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA	O
-	O
DQ	O
,	O
but	O
not	O
HLA	O
-	O
DR	O
or	O
-	O
DP	O
transcription	O
.	O

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	S-Protein
,	O
might	O
control	O
HLA	O
-	O
DQ	O
expression	O
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	S-Protein
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	O
-	O
DQ	O
in	O
another	O
CIITA	S-Protein
-	O
deficient	O
cell	O
line	O
,	O
RJ2	O
.	O
2	O
.	O
5	O
.	O

In	O
addition	O
,	O
no	O
CIITA	S-Protein
protein	O
is	O
detectable	O
in	O
clone	O
13	O
nuclear	O
extracts	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2	O
.	O
2	O
.	O
5	O
restored	O
expression	O
of	O
the	O
HLA	O
-	O
DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2	O
.	O
2	O
.	O
5	O
DQB	O
gene	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA	O
-	O
DQ	O
isotype	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
which	O
functions	O
independently	O
of	O
CIITA	S-Protein
.	O

Induction	O
of	O
cytokine	O
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin	O
-	O
stimulated	O
platelets	O
.	O

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	O
induction	O
by	O
leukocyte	O
-	O
platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte	O
-	O
platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	S-Protein
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+	O
/	O
-	O
16	O
versus	O
35	O
+	O
/	O
-	O
9	O
;	O
P	O
=	O
.	O
003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin	S-Protein
-	O
stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
,	I-Protein
1	I-Protein
beta	E-Protein
,	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
and	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
(	I-Protein
MCP	I-Protein
)	I-Protein
-	I-Protein
1	E-Protein
in	O
unfractionated	O
leukocytes	O
.	O

After	O
4	O
hours	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
and	O
IL	B-Protein
-	I-Protein
8	E-Protein
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	O
by	O
268	O
+	O
/	O
-	O
36	O
%	O
and	O
210	O
+	O
/	O
-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP	B-Protein
-	I-Protein
1	E-Protein
content	O
had	O
increased	O
by	O
170	O
+	O
/	O
-	O
8	O
%	O
.	O

Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O

Inhibition	O
of	O
binding	O
by	O
anti	O
-	O
P	B-Protein
selectin	E-Protein
antibodies	O
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	O
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte	O
-	O
platelet	O
adhesion	O
is	O
increased	O
.	O

Binding	O
of	O
activated	O
platelets	O
induces	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
,	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
and	O
MCP	B-Protein
-	I-Protein
1	E-Protein
in	O
leukocytes	O
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte	O
-	O
platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	E-Protein
CIITA	S-Protein
interacts	O
with	O
the	O
TBP	S-Protein
-	O
associated	O
factor	O
TAFII32	S-Protein
.	O

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	E-Protein
(	O
CIITA	S-Protein
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
proteins	O
.	O

Its	O
N	O
-	O
terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha	O
-	O
helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	O
-	O
helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	S-Protein
.	O

Moreover	O
,	O
a	O
CIITA	S-Protein
protein	O
in	O
which	O
both	O
functional	O
alpha	O
-	O
helices	O
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

This	O
activation	O
domain	O
of	O
CIITA	S-Protein
interacts	O
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	O
,	O
TAFII32	S-Protein
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N	O
-	O
terminal	O
deletions	O
of	O
CIITA	S-Protein
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	S-Protein
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	S-Protein
and	O
CIITA	S-Protein
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O

Regulation	O
by	O
Egr	B-Protein
-	I-Protein
1	E-Protein
,	O
c	B-Protein
-	I-Protein
Jun	E-Protein
,	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O

Biosynthesis	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O

Functional	O
analysis	O
of	O
monocytic	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-	O
182	O
to	O
-	O
37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
gene	O
in	O
response	O
to	O
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-	O
182	O
to	O
-	O
162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1	S-Protein
/	O
Egr	B-Protein
-	I-Protein
1	E-Protein
site	O
,	O
and	O
region	O
II	O
(	O
-	O
119	O
to	O
-	O
88	O
)	O
contained	O
CRE	O
and	O
NF	O
-	O
kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O

In	O
unstimulated	O
THP	O
-	O
1	O
,	O
CRE	O
-	O
binding	O
protein	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	B-Protein
-	I-Protein
Jun	E-Protein
complexes	O
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	O
site	O
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c	B-Protein
-	I-Protein
Jun	E-Protein
-	O
containing	O
complexes	O
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	O
factors	O
to	O
the	O
Egr	B-Protein
-	I-Protein
1	E-Protein
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr	B-Protein
-	I-Protein
1	E-Protein
and	O
p50	S-Protein
/	O
p65	S-Protein
,	O
respectively	O
.	O

The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	B-Protein
-	I-Protein
Jun	E-Protein
complexes	O
and	O
p50	S-Protein
/	O
p65	S-Protein
.	O

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	E-Protein
promoter	O
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O

Involvement	O
of	O
Rel	O
,	O
Fos	S-Protein
,	O
and	O
Jun	S-Protein
proteins	O
in	O
binding	O
activity	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
CD28	S-Protein
response	O
element	O
/	O
AP	O
-	O
1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O

CD28	S-Protein
is	O
an	O
important	O
costimulatory	O
molecule	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	S-Protein
leads	O
to	O
high	O
level	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	S-Protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
by	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
/	O
Rel	O
family	O
members	O
as	O
well	O
as	O
an	O
uncharacterized	O
transcription	O
factor	O
called	O
CD28	S-Protein
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
make	O
up	O
the	O
CD28	S-Protein
response	O
complex	O
transcription	O
factor	O
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	S-Protein
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP	O
-	O
1	O
-	O
binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE	O
/	O
AP	O
-	O
1	O
sequence	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP	O
-	O
1	O
site	O
.	O

Of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
tested	O
,	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
contains	O
predominantly	O
c	B-Protein
-	I-Protein
Rel	E-Protein
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	S-Protein
and	O
RelA	S-Protein
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	O
.	O

c	B-Protein
-	I-Protein
Fos	E-Protein
and	O
c	B-Protein
-	I-Protein
Jun	E-Protein
are	O
also	O
found	O
in	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP	O
-	O
1	O
-	O
binding	O
sites	O
influence	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
activity	O
in	O
CD28	S-Protein
-	O
costimulated	O
T	O
cells	O
.	O

c	B-Protein
-	I-Protein
Myb	E-Protein
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	S-Protein
.	O

The	O
Zfh	O
family	O
of	O
zinc	O
finger	O
/	O
homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	S-Protein
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh	O
-	O
1	O
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	S-Protein
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	B-Protein
-	I-Protein
Myb	E-Protein
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	S-Protein
blocks	O
the	O
activity	O
of	O
c	B-Protein
-	I-Protein
Myb	E-Protein
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	B-Protein
-	I-Protein
Myb	E-Protein
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	S-Protein
and	O
transcriptional	O
activation	O
by	O
c	B-Protein
-	I-Protein
Myb	E-Protein
/	O
Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-Protein
integrin	E-Protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

GABP	O
factors	O
bind	O
to	O
a	O
distal	O
interleukin	B-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
enhancer	O
and	O
contribute	O
to	O
c	B-Protein
-	I-Protein
Raf	E-Protein
-	O
mediated	O
increase	O
in	O
IL	B-Protein
-	I-Protein
2	E-Protein
induction	O
.	O

Triggering	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
-	O
CD3	O
complex	O
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2	O
+	O
-	O
dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	O
kinase	O
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B-Protein
2	E-Protein
(	B-Protein
IL	I-Protein
-	I-Protein
2	E-Protein
)	O
gene	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Prominent	O
protein	O
kinase	O
cascades	O
are	O
those	O
that	O
activate	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O

We	O
show	O
here	O
that	O
c	B-Protein
-	I-Protein
Raf	E-Protein
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP	O
-	O
Erk	O
cascade	O
,	O
contributes	O
to	O
IL	B-Protein
-	I-Protein
2	E-Protein
induction	O
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-	O
502	O
to	O
-	O
413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
gene	O
.	O

Induction	O
of	O
this	O
distal	O
IL	B-Protein
-	I-Protein
2	E-Protein
enhancer	O
differs	O
from	O
induction	O
of	O
the	O
proximal	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
-	O
enhancer	O
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2	O
+	O
signals	O
.	O

In	O
DNA	O
-	O
protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	O
factors	O
GABP	B-Protein
alpha	E-Protein
and	O
-	B-Protein
beta	E-Protein
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets	O
-	O
like	O
factors	O
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
-	O
enhancer	O
,	O
while	O
overexpression	O
of	O
both	O
GABP	O
factors	O
enhanced	O
the	O
IL	B-Protein
-	I-Protein
2	E-Protein
promoter	O
-	O
enhancer	O
induction	O
.	O

Overexpression	O
of	O
BXB	S-Protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c	B-Protein
-	I-Protein
Raf	E-Protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
Erk	O
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	O
-	O
mediated	O
promoter	O
-	O
enhancer	O
induction	O
.	O

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c	B-Protein
-	I-Protein
Raf	E-Protein
-	O
induced	O
phosphorylation	O
of	O
GABP	O
factors	O
(	O
E	O
.	O
Flory	O
,	O
A	O
.	O
Hoffmeyer	O
,	O
U	O
.	O
Smola	O
,	O
U	O
.	O
R	O
.	O
Rapp	O
,	O
and	O
J	O
.	O
T	O
.	O
Bruder	O
,	O
J	O
.	O
Virol	O
.	O
70	O
:	O
2260	O
-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	O
factors	O
to	O
the	O
Raf	O
-	O
mediated	O
enhancement	O
of	O
IL	B-Protein
-	I-Protein
2	E-Protein
induction	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	O
eotaxin	S-Protein
gene	O
.	O

Eotaxin	S-Protein
is	O
an	O
eosinophil	O
specific	O
beta	O
-	O
chemokine	O
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Its	O
expression	O
is	O
stimulus	O
-	O
and	O
cell	O
-	O
specific	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	S-Protein
gene	O
.	O

Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	O
eotaxin	S-Protein
gene	O
expression	O
and	O
/	O
or	O
mediating	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	O
with	O
nuclear	O
factors	O
like	O
NF	B-Protein
-	I-Protein
IL6	E-Protein
,	O
AP	O
-	O
1	O
,	O
a	O
NF	O
-	O
kappa	O
-	O
B	O
like	O
consensus	O
sequence	O
and	O
gamma	B-Protein
-	I-Protein
interferon	E-Protein
-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/	O
Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
in	O
human	O
THP	O
-	O
1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50	O
/	O
p65	O
containing	O
NF	O
-	O
kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL	O
-	O
8	O
.	O

This	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O

The	O
oxLDL	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	E-Protein
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	O
prevented	O
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	E-Protein
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
expression	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
and	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	E-Protein
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	E-Protein
(	O
CIITA	S-Protein
)	O
is	O
a	O
bi	O
-	O
or	O
multi	O
-	O
functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	S-Protein
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN	B-Protein
-	I-Protein
gamma	E-Protein
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O

CD30	S-Protein
-	O
dependent	O
degradation	O
of	O
TRAF2	S-Protein
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	S-Protein
is	O
a	O
cell	O
-	O
surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

CD30	S-Protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	S-Protein
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B-Protein
1	I-Protein
tumor	I-Protein
necrosis	I-Protein
factor	I-Protein
receptor	E-Protein
(	O
TNFR1	S-Protein
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	O
-	O
binding	O
sites	O
within	O
the	O
CD30	S-Protein
cytoplasmic	O
domain	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	S-Protein
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	S-Protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O

During	O
CD30	S-Protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	S-Protein
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	S-Protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	S-Protein
and	O
the	O
associated	O
protein	O
TRAF1	S-Protein
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	S-Protein
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	S-Protein
.	O

Depletion	O
of	O
intracellular	O
TRAF2	S-Protein
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death	O
-	O
inducing	O
receptors	O
such	O
as	O
TNFR1	S-Protein
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
TRAF2	S-Protein
was	O
found	O
to	O
potentiate	O
TNFR1	S-Protein
-	O
mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	S-Protein
,	O
as	O
well	O
as	O
other	O
TRAF	O
-	O
binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

TNFalpha	S-Protein
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV	O
-	O
1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O

Activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	S-Protein
.	O

Ctx	O
combined	O
with	O
TNFalpha	S-Protein
or	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-Protein
antigen	E-Protein
production	O
in	O
U1	O
promonocytic	O
cells	O
.	O

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-	O
mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	S-Protein
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	S-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
cooperate	O
differently	O
with	O
the	O
cAMP	O
/	O
PKA	O
activation	O
pathway	O
to	O
induce	O
HIV	O
-	O
1	O
expression	O
in	O
U1	O
cells	O
.	O

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP	O
-	O
1	O
-	O
dependent	O
transcription	O
.	O

TNFalpha	S-Protein
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP	O
-	O
1	O
-	O
mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	S-Protein
and	O
the	O
cAMP	O
/	O
PKA	O
pathway	O
.	O

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
cannot	O
bind	O
CREB	O
/	O
ATF	O
homodimers	O
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV	O
-	O
1	O
DSE	O
bind	O
heterodimers	O
composed	O
of	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
proteins	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
product	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
engages	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	E-Protein
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	O
-	O
kappaB	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
(	O
LMP1	S-Protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	S-Protein
is	O
a	O
constitutively	O
activated	O
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
.	O

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	O
residues	O
beyond	O
TES1	O
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	O
interacting	O
proteins	O
,	O
including	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	E-Protein
(	O
TRADD	S-Protein
)	O
.	O

TRADD	S-Protein
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	O
-	O
type	O
TES2	O
and	O
not	O
with	O
isoleucine	O
-	O
mutated	O
TES2	O
.	O

TRADD	S-Protein
associated	O
with	O
wild	O
-	O
type	O
LMP1	S-Protein
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	S-Protein
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	S-Protein
constitutively	O
associated	O
with	O
LMP1	S-Protein
in	O
EBV	O
-	O
transformed	O
cells	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	S-Protein
and	O
TES2	S-Protein
synergistically	O
mediated	O
high	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	S-Protein
appropriates	O
TRADD	S-Protein
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	O
inducible	O
Oct	B-Protein
-	I-Protein
2	E-Protein
gene	O
expression	O
in	O
precursor	O
B	O
lymphocytes	O
.	O

The	O
POU	O
transcription	O
factors	O
Oct	B-Protein
-	I-Protein
1	E-Protein
and	O
Oct	B-Protein
-	I-Protein
2	E-Protein
regulate	O
the	O
activity	O
of	O
octamer	O
-	O
dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	O
genes	O
.	O

Unlike	O
Oct	B-Protein
-	I-Protein
1	E-Protein
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct	B-Protein
-	I-Protein
2	E-Protein
expression	O
is	O
restricted	O
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	O
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct	B-Protein
-	I-Protein
2	E-Protein
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
an	O
LPS	O
-	O
responsive	O
member	O
of	O
the	O
Rel	O
transcription	O
factor	O
family	O
.	O

Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct	B-Protein
-	I-Protein
2	E-Protein
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct	B-Protein
-	I-Protein
2	E-Protein
-	O
directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct	B-Protein
-	I-Protein
2	E-Protein
gene	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct	B-Protein
-	I-Protein
1	E-Protein
was	O
unaffected	O
.	O

The	O
finding	O
that	O
Oct	B-Protein
-	I-Protein
2	E-Protein
is	O
under	O
NF	O
-	O
kappaB	O
control	O
highlights	O
an	O
important	O
cross	O
-	O
talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	O
factor	O
families	O
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O

Paternal	O
expression	O
of	O
WT1	S-Protein
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	S-Protein
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
WT1	S-Protein
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i	O
.	O
e	O
.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	S-Protein
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	S-Protein
and	O
H19	S-Protein
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	S-Protein
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	S-Protein
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue	O
-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct	B-Protein
-	I-Protein
2	E-Protein
,	O
OBF	B-Protein
-	I-Protein
1	E-Protein
,	O
PU	B-Protein
.	I-Protein
1	E-Protein
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF	O
-	O
kappa	O
B	O
,	O
E47	S-Protein
)	O
.	O

By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct	B-Protein
-	I-Protein
2	E-Protein
and	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell	O
-	O
expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O

Regulation	O
of	O
Id3	S-Protein
cell	O
cycle	O
function	O
by	O
Cdk	B-Protein
-	I-Protein
2	E-Protein
-	O
dependent	O
phosphorylation	O
.	O

The	O
functions	O
of	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
in	O
activating	O
differentiation	O
-	O
linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	O
family	O
of	O
HLH	O
proteins	O
.	O

These	O
bHLH	O
antagonists	O
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	O
targets	O
in	O
inactive	O
heterodimers	O
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	O
regulatory	O
(	O
E	O
box	O
)	O
sequences	O
.	O

Recently	O
,	O
cyclin	B-Protein
E	E-Protein
-	O
Cdk2	S-Protein
-	O
and	O
cyclin	B-Protein
A	E-Protein
-	O
Cdk2	S-Protein
-	O
dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	S-Protein
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	S-Protein
in	O
abrogating	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E	O
.	O
Hara	O
,	O
M	O
.	O
Hall	O
,	O
and	O
G	O
.	O
Peters	O
,	O
EMBO	O
J	O
.	O
16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell	O
-	O
cycle	O
-	O
regulated	O
phosphorylation	O
of	O
Id3	S-Protein
alters	O
the	O
specificity	O
of	O
Id3	S-Protein
for	O
abrogating	O
both	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E	O
-	O
box	O
-	O
dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild	O
-	O
type	O
Id3	S-Protein
,	O
an	O
Id3	S-Protein
Asp5	O
mutant	O
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	S-Protein
Ala5	O
mutant	O
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	O
-	O
type	O
Id3	S-Protein
protein	O
.	O

Cdk2	S-Protein
-	O
dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	S-Protein
and	O
modulates	O
its	O
target	O
bHLH	O
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	S-Protein
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	O
heterodimer	O
-	O
dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	S-Protein
and	O
Id	O
-	O
bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	S-Protein
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL	B-Protein
-	I-Protein
2	E-Protein
in	O
Th1	O
cells	O
and	O
by	O
IL	B-Protein
-	I-Protein
4	E-Protein
in	O
Th2	O
cells	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	S-Protein
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	S-Protein
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	S-Protein
induction	O
was	O
completely	O
inhibited	O
by	O
IL	B-Protein
-	I-Protein
2	E-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
4	E-Protein
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	S-Protein
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up	O
-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	O
of	O
IkappaBalpha	S-Protein
expression	O
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	O
natural	O
antibodies	O
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O

Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1	O
.	O
5	O
dynes	O
/	O
cm2	O
)	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U	O
/	O
ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	O
molecules	O
and	O
chemoattractants	O
.	O

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF	O
-	O
kappa	O
B	O
(	O
p65	S-Protein
subunit	O
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
this	O
setting	O
.	O

At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O

Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl	O
-	O
phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte	O
-	O
endothelium	O
interaction	O
possibly	O
through	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O

IL	B-Protein
-	I-Protein
2	E-Protein
-	O
induced	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF	O
-	O
kappaB	O
induction	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	E-Protein
expression	O
.	O

The	O
binding	O
of	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
(	O
IL	B-Protein
-	I-Protein
2	E-Protein
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	O
nuclear	O
expression	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2R	I-Protein
)	I-Protein
alpha	I-Protein
chain	E-Protein
gene	O
,	O
and	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL	O
-	O
2R	O
signaling	O
in	O
the	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O

Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8	O
+	O
T	O
-	O
PLL	O
expressed	O
IL	B-Protein
-	I-Protein
2Ralpha	E-Protein
and	O
beta	S-Protein
chains	O
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL	B-Protein
-	I-Protein
2Ralpha	E-Protein
expression	O
on	O
culture	O
with	O
exogeneous	O
IL	B-Protein
-	I-Protein
2	E-Protein
.	O

Northern	O
blot	O
analysis	O
failed	O
to	O
detect	O
IL	B-Protein
-	I-Protein
2	E-Protein
mRNA	O
,	O
suggesting	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
revealed	O
that	O
recombinant	O
IL	B-Protein
-	I-Protein
2	E-Protein
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF	O
-	O
kappaB	O
components	O
c	B-Protein
-	I-Protein
Rel	E-Protein
and	O
KBF1	S-Protein
in	O
these	O
cells	O
.	O

IL	B-Protein
-	I-Protein
2	E-Protein
binding	O
analysis	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL	O
-	O
2Rs	O
on	O
the	O
leukemia	O
cells	O
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high	O
-	O
affinity	O
IL	O
-	O
2Rs	O
.	O

These	O
results	O
show	O
that	O
IL	B-Protein
-	I-Protein
2	E-Protein
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
CD8	O
+	O
T	O
-	O
PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	O
T	O
-	O
cell	O
-	O
line	O
-	O
expressing	O
wild	O
-	O
type	O
and	O
mutated	O
CD4	B-Protein
receptors	E-Protein
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	S-Protein
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
induced	O
apoptosis	O
(	O
J	O
.	O
Corbeil	O
,	O
M	O
.	O
Tremblay	O
,	O
and	O
D	O
.	O
D	O
.	O
Richman	O
,	O
J	O
.	O
Exp	O
.	O
Med	O
.	O
183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	S-Protein
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O

To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	S-Protein
cytoplasmic	O
tail	O
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2	O
.	O
01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	S-Protein
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
(	O
mutated	O
at	O
the	O
dicysteine	O
motif	O
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild	O
-	O
type	O
CD4	S-Protein
.	O

The	O
differences	O
between	O
wild	O
-	O
type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
or	O
NF	O
-	O
kappaB	O
activation	O
.	O

Initial	O
signaling	O
through	O
the	O
CD4	B-Protein
receptor	E-Protein
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8	O
-	O
2	O
,	O
which	O
binds	O
to	O
CD4	S-Protein
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	S-Protein
-	O
Fas	B-Protein
ligand	E-Protein
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	S-Protein
MAb	O
(	O
ZB	O
-	O
4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	S-Protein
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	S-Protein
-	O
Fas	B-Protein
ligand	E-Protein
interaction	O
,	O
does	O
not	O
require	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	S-Protein
dimerization	O
.	O

NF	O
-	O
kappaB	O
only	O
partially	O
mediates	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
activation	O
of	O
B	O
cells	O
.	O

The	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	E-Protein
(	O
LMP1	S-Protein
)	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O

LMP1	S-Protein
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
activation	O
markers	O
.	O

LMP1	S-Protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
one	O
through	O
interactions	O
with	O
TRAF	O
proteins	O
and	O
the	O
other	O
with	O
the	O
TRADD	O
protein	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF	O
-	O
kappaB	O
induction	O
in	O
the	O
up	O
-	O
regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM	B-Protein
-	I-Protein
1	E-Protein
and	O
CD71	S-Protein
by	O
LMP1	S-Protein
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	S-Protein
activates	O
transcription	O
from	O
p50	S-Protein
/	O
p65	S-Protein
-	O
and	O
c	B-Protein
-	I-Protein
Rel	E-Protein
-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	O
IkappaB	O
mutant	O
.	O

ICAM	B-Protein
-	I-Protein
1	E-Protein
and	O
CD71	S-Protein
are	O
nevertheless	O
up	O
-	O
regulated	O
by	O
LMP1	S-Protein
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	O
IkappaB	O
.	O

Furthermore	O
,	O
LMP1	S-Protein
-	O
induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	S-Protein
is	O
unable	O
to	O
activate	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	O
that	O
LMP1	S-Protein
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF	O
-	O
kappaB	O
.	O

Relationship	O
between	O
IkappaBalpha	S-Protein
constitutive	O
expression	O
,	O
TNFalpha	S-Protein
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	S-Protein
into	O
lymphoblastoid	O
cells	O
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	S-Protein
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	O
cell	O
cycle	O
analysis	O
after	O
BrdU	O
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in	O
-	O
situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O

No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	S-Protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	O
clones	O
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	S-Protein
transfected	O
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	S-Protein
treatment	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	S-Protein
treatment	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	O
cells	O
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	S-Protein
gene	O
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	S-Protein
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	O
.	O

Uncoupling	O
activation	O
-	O
dependent	O
HS1	S-Protein
phosphorylation	O
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	S-Protein
and	O
CD28	S-Protein
.	O

CD3	O
,	O
CD2	S-Protein
,	O
and	O
CD28	S-Protein
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	S-Protein
,	O
Cbl	S-Protein
,	O
p85	O
phosphoinositide	O
3	O
-	O
kinase	O
,	O
and	O
the	O
Src	S-Protein
family	O
kinases	O
Lck	S-Protein
and	O
Fyn	S-Protein
.	O

Ligation	O
of	O
CD3	O
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	S-Protein
,	O
a	O
75	O
-	O
kDa	O
hematopoietic	O
cell	O
-	O
specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O

We	O
have	O
examined	O
changes	O
in	O
HS1	S-Protein
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	O
,	O
CD2	S-Protein
,	O
and	O
CD28	S-Protein
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti	O
-	O
CD28	S-Protein
mAb	O
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	S-Protein
ligands	O
CD80	S-Protein
or	O
CD86	S-Protein
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	S-Protein
in	O
Jurkat	O
T	O
cells	O
.	O

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	S-Protein
was	O
induced	O
by	O
mitogenic	O
pairs	O
of	O
anti	O
-	O
CD2	S-Protein
mAbs	O
capable	O
of	O
activating	O
the	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
.	O

Costimulation	O
through	O
CD28	S-Protein
and	O
/	O
or	O
CD2	S-Protein
did	O
not	O
modulate	O
the	O
CD3	O
-	O
dependent	O
phosphorylation	O
of	O
HS1	S-Protein
.	O

In	O
vivo	O
studies	O
indicated	O
that	O
CD3	O
-	O
induced	O
HSI	S-Protein
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	S-Protein
family	O
tyrosine	O
kinase	O
Lck	S-Protein
and	O
the	O
tyrosine	O
phosphatase	O
CD45	S-Protein
,	O
did	O
not	O
require	O
MEK1	S-Protein
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	S-Protein
,	O
and	O
CD2	S-Protein
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	S-Protein
.	O

Furthermore	O
,	O
activation	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	S-Protein
was	O
not	O
required	O
for	O
NFAT	O
transcriptional	O
activation	O
.	O

IL	B-Protein
-	I-Protein
7	E-Protein
reconstitutes	O
multiple	O
aspects	O
of	O
v	B-Protein
-	I-Protein
Abl	E-Protein
-	O
mediated	O
signaling	O
.	O

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	B-Protein
-	I-Protein
Abl	E-Protein
is	O
currently	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL	B-Protein
-	I-Protein
4	E-Protein
and	O
IL	B-Protein
-	I-Protein
7	E-Protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-Protein
protein	I-Protein
kinase	I-Protein
(	I-Protein
JAK	I-Protein
)	I-Protein
1	E-Protein
,	O
JAK3	S-Protein
,	O
STAT5	O
,	O
and	O
STAT6	S-Protein
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	B-Protein
-	I-Protein
Abl	E-Protein
.	O

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	B-Protein
-	I-Protein
Abl	E-Protein
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL	B-Protein
-	I-Protein
4	E-Protein
and	O
IL	B-Protein
-	I-Protein
7	E-Protein
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	O
-	O
sensitive	O
v	B-Protein
-	I-Protein
Abl	E-Protein
mutant	O
were	O
examined	O
.	O

Whereas	O
IL	B-Protein
-	I-Protein
4	E-Protein
had	O
little	O
or	O
no	O
effect	O
,	O
IL	B-Protein
-	I-Protein
7	E-Protein
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	O
-	O
Abl	O
kinase	O
inactivation	O
.	O

IL	B-Protein
-	I-Protein
7	E-Protein
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c	B-Protein
-	I-Protein
Myc	E-Protein
,	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
,	O
and	O
Bcl	B-Protein
-	I-Protein
xL	E-Protein
that	O
occur	O
upon	O
loss	O
of	O
v	O
-	O
Abl	O
kinase	O
activity	O
.	O

IL	B-Protein
-	I-Protein
7	E-Protein
did	O
not	O
maintain	O
v	B-Protein
-	I-Protein
Abl	E-Protein
-	O
mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL	B-Protein
-	I-Protein
7	E-Protein
.	O

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL	B-Protein
-	I-Protein
7	E-Protein
signaling	O
pathways	O
in	O
transformation	O
by	O
v	B-Protein
-	I-Protein
Abl	E-Protein
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL	B-Protein
-	I-Protein
4	E-Protein
and	O
IL	B-Protein
-	I-Protein
7	E-Protein
signaling	O
cannot	O
substitute	O
for	O
an	O
active	O
v	B-Protein
-	I-Protein
Abl	E-Protein
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O

p21ras	S-Protein
initiates	O
Rac	B-Protein
-	I-Protein
1	E-Protein
but	O
not	O
phosphatidyl	O
inositol	O
3	O
kinase	O
/	O
PKB	S-Protein
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	S-Protein
is	O
activated	O
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-Protein
-	I-Protein
1	E-Protein
and	O
the	O
Ras	O
-	O
related	O
GTPase	O
Rac	B-Protein
-	I-Protein
1	E-Protein
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PtdIns	O
3	O
-	O
kinase	O
)	O
.	O

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac	B-Protein
-	I-Protein
1	E-Protein
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	S-Protein
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	O
/	O
threonine	O
kinase	O
Akt	S-Protein
/	O
PKB	S-Protein
.	O

The	O
role	O
of	O
PtdIns	O
3	O
-	O
kinase	O
in	O
Ras	O
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3	O
-	O
kinase	O
to	O
initiate	O
the	O
Rac	B-Protein
-	I-Protein
1	E-Protein
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	S-Protein
/	O
PKB	S-Protein
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac	B-Protein
-	I-Protein
1	E-Protein
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP	O
-	O
1	O
complexes	O
.	O

PtdIns	O
3	O
-	O
kinase	O
signals	O
cannot	O
mimic	O
p21ras	S-Protein
and	O
induce	O
the	O
Rac	O
mediated	O
responses	O
of	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	O
or	O
Ras	O
activation	O
of	O
AP	O
-	O
1	O
is	O
dependent	O
on	O
PtdIns	O
3	O
-	O
kinase	O
.	O

PKB	S-Protein
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	S-Protein
signals	O
are	O
unable	O
to	O
induce	O
Akt	S-Protein
/	O
PKB	S-Protein
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	O
function	O
required	O
for	O
Akt	S-Protein
/	O
PKB	S-Protein
activation	O
in	O
response	O
to	O
the	O
TCR	O
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3	O
-	O
kinase	O
and	O
Akt	S-Protein
/	O
PKB	S-Protein
are	O
not	O
universal	O
Ras	O
effector	O
molecules	O
.	O

Ras	O
can	O
initiate	O
Rac	B-Protein
-	I-Protein
1	E-Protein
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
.	O

Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	O
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3	O
/	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	O
expression	O
of	O
TCRzeta	S-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
that	O
are	O
associated	O
with	O
the	O
TCR	O
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	S-Protein
containing	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
complexes	O
have	O
been	O
noted	O
.	O

These	O
defects	O
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	S-Protein
,	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	O
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	O
therapy	O
[	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	E-Protein
,	O
IFN	B-Protein
alpha	E-Protein
-	O
containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	S-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
were	O
determined	O
by	O
Western	O
blots	O
of	O
T	O
-	O
cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	O
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
.	O

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	O
treatment	O
were	O
also	O
investigated	O
.	O

TCRzeta	S-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
were	O
detected	O
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	S-Protein
(	O
P	O
=	O
0	O
.	O
029	O
)	O
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
(	O
P	O
=	O
0	O
.	O
029	O
)	O
but	O
not	O
CD3epsilon	S-Protein
(	O
P	O
=	O
0	O
.	O
131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL	B-Protein
-	I-Protein
2	E-Protein
/	O
IFN	B-Protein
alpha	E-Protein
-	O
based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	S-Protein
increased	O
significantly	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	O
of	O
TCRzeta	S-Protein
or	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	S-Protein
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

Abnormal	O
NFkappaB	O
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
and	O
/	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O

Activation	O
of	O
NFkappaB	O
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	O
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	O
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	O
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	S-Protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	S-Protein
levels	O
were	O
present	O
although	O
kappaB	O
binding	O
was	O
not	O
inducible	O
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	S-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	E-Protein
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	S-Protein
associated	O
molecules	O
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	O
-	O
based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	O
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL	B-Protein
-	I-Protein
2	E-Protein
/	O
IFN	B-Protein
alpha	E-Protein
-	O
based	O
treatment	O
.	O

This	O
alteration	O
in	O
NFkappaB	O
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta	S-Protein
-	O
associated	O
signaling	O
elements	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

Transcriptional	O
regulation	O
of	O
lysosomal	B-Protein
acid	I-Protein
lipase	E-Protein
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	O
factors	O
Sp1	S-Protein
and	O
AP	O
-	O
2	O
.	O

Human	O
lysosomal	B-Protein
acid	I-Protein
lipase	E-Protein
(	O
LAL	S-Protein
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	S-Protein
-	O
mRNA	O
is	O
induced	O
.	O

This	O
induction	O
is	O
dependent	O
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O

The	O
cell	O
type	O
-	O
specific	O
increase	O
in	O
LAL	S-Protein
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O

In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-	O
182	O
bp	O
and	O
-	O
107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	S-Protein
and	O
AP	O
-	O
2	O
to	O
the	O
LAL	S-Protein
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	S-Protein
and	O
AP	O
-	O
2	O
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	O
LAL	S-Protein
expression	O
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B-Protein
acid	I-Protein
lipase	E-Protein
(	O
LAL	S-Protein
)	O
expression	O
in	O
THP	O
-	O
1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	S-Protein
and	O
AP	O
-	O
2	O
.	O

A	O
nongenomic	O
mechanism	O
for	O
progesterone	O
-	O
mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K	O
+	O
channels	O
,	O
Ca2	O
+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage	O
-	O
gated	O
and	O
calcium	O
-	O
activated	O
K	O
+	O
channels	O
(	O
KV	O
and	O
KCa	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2	O
+	O
signaling	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
-	O
driven	O
gene	O
expression	O
are	O
inhibited	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2	O
+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2	O
+	O
signals	O
,	O
but	O
not	O
the	O
Ca2	O
+	O
transient	O
after	O
TCR	O
stimulation	O
.	O

K	O
+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	O
and	O
KCa	O
channels	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K	O
+	O
channels	O
,	O
reducing	O
both	O
Kv1	B-Protein
.	I-Protein
3	E-Protein
and	O
charybdotoxin	O
-	O
resistant	O
components	O
of	O
KV	O
current	O
and	O
KCa	O
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	O
KV	O
channels	O
expressed	O
in	O
cell	O
lines	O
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	O
voltage	O
-	O
gated	O
Na	O
+	O
channel	O
,	O
an	O
inward	O
rectifier	O
K	O
+	O
channel	O
,	O
or	O
on	O
lymphocyte	O
Ca2	O
+	O
and	O
Cl	O
-	O
channels	O
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K	O
+	O
channels	O
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone	O
-	O
induced	O
immunosuppression	O
.	O

Role	O
of	O
IKK1	S-Protein
and	O
IKK2	S-Protein
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O

Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
transcription	O
factor	O
family	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
1	O
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	S-Protein
and	O
IKK2	S-Protein
.	O

Phosphorylation	O
of	O
the	O
IkappaB	O
cytoplasmic	O
inhibitors	O
,	O
IkappaBalpha	S-Protein
,	O
IkappaBbeta	S-Protein
,	O
and	O
IkappaBepsilon	S-Protein
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
proteins	O
into	O
the	O
nucleus	O
.	O

At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	O
activity	O
in	O
human	O
monocytes	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	O
and	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	S-Protein
,	O
a	O
dominant	O
negative	O
mutant	O
IKK1	S-Protein
(	O
K44M	O
)	O
,	O
or	O
wild	O
type	O
IKK2	S-Protein
did	O
not	O
affect	O
LPS	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
monocytic	O
cells	O
.	O

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	S-Protein
inhibited	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
IKK2	S-Protein
.	O

Effects	O
of	O
overexpression	O
of	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
on	O
NFkappaB	O
activation	O
,	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
and	O
stress	O
-	O
activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O

The	O
association	O
and	O
activation	O
of	O
the	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
protein	O
kinase	O
(	O
IRAK	O
)	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL	O
-	O
1	O
signal	O
transduction	O
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6	O
.	O
1	O
overexpressing	O
human	O
(	O
h	O
)	O
IRAK	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL	O
-	O
1	O
signaling	O
.	O

Overexpression	O
of	O
hIRAK	O
enhanced	O
IL	O
-	O
1	O
-	O
stimulated	O
activation	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N	O
-	O
IRAK	O
)	O
specifically	O
inhibited	O
IL	O
-	O
1	O
-	O
dependent	O
NFkappaB	O
activity	O
.	O

In	O
clones	O
stably	O
overexpressing	O
hIRAK	O
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	O
correlated	O
with	O
a	O
low	O
basal	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL	O
-	O
1	O
-	O
dependent	O
manner	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose	O
-	O
response	O
curve	O
of	O
IL	O
-	O
1	O
-	O
induced	O
IL	B-Protein
-	I-Protein
2	E-Protein
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	O
directly	O
triggers	O
NFkappaB	O
-	O
mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
:	O
permanent	O
overexpression	O
of	O
IRAK	O
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
SAP	O
kinases	O
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Decreased	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O

IL	O
-	O
12	O
is	O
a	O
75	O
-	O
kDa	O
heterodimeric	O
cytokine	O
composed	O
of	O
two	O
covalently	O
linked	O
p35	S-Protein
and	O
p40	S-Protein
chains	O
.	O

This	O
pro	O
-	O
inflammatory	O
cytokine	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

Thus	O
,	O
IL	O
-	O
12	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti	O
-	O
inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
.	O

ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL	O
-	O
12	O
heterodimer	O
as	O
well	O
as	O
p40	S-Protein
monomer	O
by	O
human	O
monocytic	O
cells	O
.	O

This	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
12p40	E-Protein
mRNA	O
expression	O
.	O

Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	S-Protein
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
and	O
binding	O
to	O
the	O
p40	S-Protein
-	O
kappaB	O
site	O
in	O
the	O
p40	S-Protein
promoter	O
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	S-Protein
gene	O
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
ASA	O
leads	O
to	O
down	O
-	O
regulation	O
of	O
IL	O
-	O
12	O
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

Membrane	O
-	O
associated	O
lymphotoxin	O
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pathway	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	O
molecule	O
expression	O
and	O
cytokine	O
secretion	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell	O
-	O
mediated	O
EC	O
activation	O
.	O

METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E	B-Protein
-	I-Protein
selectin	E-Protein
or	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
8	E-Protein
promoters	O
or	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
.	O

In	O
addition	O
,	O
a	O
dominant	O
-	O
negative	O
mutant	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
I	E-Protein
(	O
TNFRI	S-Protein
)	O
expression	O
vector	O
was	O
co	O
-	O
transfected	O
in	O
inhibition	O
studies	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Co	O
-	O
culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E	B-Protein
-	I-Protein
selectin	E-Protein
,	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
activity	O
.	O

NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p50	S-Protein
and	O
p65	S-Protein
)	O
.	O

Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin	B-Protein
-	I-Protein
alpha	E-Protein
(	O
LTalpha	S-Protein
)	O
but	O
not	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
.	O

Furthermore	O
,	O
LTalpha	S-Protein
was	O
secreted	O
in	O
NK	O
:	O
EC	O
co	O
-	O
cultures	O
.	O

Co	O
-	O
transfection	O
with	O
dominant	O
-	O
negative	O
mutant	O
TNFRI	S-Protein
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti	O
-	O
human	O
LT	O
sera	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	S-Protein
,	O
leading	O
to	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
transcription	O
of	O
E	B-Protein
-	I-Protein
selectin	E-Protein
and	O
IL	B-Protein
-	I-Protein
8	E-Protein
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	O
TNFRI	S-Protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
.	O

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-	O
associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	E-Protein
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O

Receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	E-Protein
(	O
RANK	S-Protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O

Its	O
cognate	O
ligand	O
(	O
RANKL	S-Protein
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	S-Protein
with	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factors	I-Protein
(	I-Protein
TRAFs	I-Protein
)	I-Protein
1	E-Protein
,	O
2	S-Protein
,	O
3	S-Protein
,	O
5	S-Protein
,	O
and	O
6	S-Protein
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	O
/	O
RANK	S-Protein
interaction	O
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	S-Protein
cytoplasmic	O
tail	O
.	O

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	S-Protein
-	O
dependent	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
c	B-Protein
-	I-Protein
Jun	E-Protein
NH2	O
-	O
terminal	O
kinase	O
activities	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O

In	O
particular	O
,	O
TRAF6	S-Protein
interacted	O
with	O
membrane	O
-	O
proximal	O
determinants	O
distinct	O
from	O
those	O
binding	O
TRAFs	B-Protein
1	E-Protein
,	O
2	S-Protein
,	O
3	S-Protein
,	O
and	O
5	S-Protein
.	O

When	O
this	O
membrane	O
-	O
proximal	O
TRAF6	S-Protein
interaction	O
domain	O
was	O
deleted	O
,	O
RANK	S-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
signaling	O
was	O
completely	O
inhibited	O
while	O
c	B-Protein
-	I-Protein
Jun	E-Protein
NH2	O
-	O
terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2	O
-	O
terminal	O
truncation	O
mutant	O
of	O
TRAF6	S-Protein
inhibited	O
RANKL	S-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	S-Protein
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O

Regulation	O
of	O
interleukin	B-Protein
-	I-Protein
1beta	E-Protein
transcription	O
by	O
Epstein	O
-	O
Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	O
proteins	O
via	O
their	O
interaction	O
with	O
RBP	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin	B-Protein
-	I-Protein
1beta	E-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	O
proteins	O
on	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
.	O

Using	O
RT	O
-	O
PCR	O
,	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
was	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
EBV	O
-	O
transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O

The	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
,	O
EBV	B-Protein
nuclear	I-Protein
proteins	I-Protein
2	E-Protein
,	O
3	S-Protein
,	O
4	S-Protein
,	O
and	O
6	B-Protein
genes	E-Protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-	O
300	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B-Protein
nuclear	I-Protein
proteins	I-Protein
3	E-Protein
and	O
6	S-Protein
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	O
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O

In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF	O
-	O
kappaB	O
,	O
only	O
RBP	O
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
could	O
be	O
demonstrated	O
in	O
EBV	O
-	O
transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
led	O
to	O
activation	O
of	O
NF	O
-	O
kappaB	O
that	O
was	O
capable	O
of	O
binding	O
the	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
promoter	O
.	O

The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up	O
-	O
regulate	O
IL	B-Protein
-	I-Protein
1beta	E-Protein
expression	O
,	O
possibly	O
by	O
using	O
RBP	O
,	O
NF	O
-	O
kappaB	O
,	O
or	O
both	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Characterization	O
of	O
the	O
human	O
elk	B-Protein
-	I-Protein
1	E-Protein
promoter	O
.	O

Potential	O
role	O
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk	B-Protein
-	I-Protein
1	E-Protein
gene	O
expression	O
in	O
monocytes	O
.	O

To	O
characterize	O
the	O
human	O
elk	B-Protein
-	I-Protein
1	E-Protein
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk	B-Protein
-	I-Protein
1	E-Protein
-	O
specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O

A	O
TATA	O
-	O
like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	O
for	O
elk	B-Protein
-	I-Protein
1	E-Protein
transcription	O
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	O
to	O
elk	B-Protein
-	I-Protein
1	E-Protein
promoter	O
activity	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	O
Elk	B-Protein
-	I-Protein
1	E-Protein
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk	B-Protein
-	I-Protein
1	E-Protein
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk	B-Protein
-	I-Protein
1	E-Protein
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

Egr	B-Protein
-	I-Protein
1	E-Protein
and	O
the	O
serum	B-Protein
response	I-Protein
factor	E-Protein
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+	O
265	O
and	O
+	O
448	O
,	O
respectively	O
.	O

Because	O
Egr	B-Protein
-	I-Protein
1	E-Protein
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk	B-Protein
-	I-Protein
1	E-Protein
expression	O
,	O
we	O
propose	O
that	O
Egr	B-Protein
-	I-Protein
1	E-Protein
is	O
important	O
for	O
the	O
regulation	O
of	O
elk	B-Protein
-	I-Protein
1	E-Protein
transcription	O
in	O
differentiating	O
monocytes	O
.	O

Functional	O
association	O
of	O
Nmi	S-Protein
with	O
Stat5	O
and	O
Stat1	S-Protein
in	O
IL	B-Protein
-	I-Protein
2	E-Protein
-	O
and	O
IFNgamma	S-Protein
-	O
mediated	O
signaling	O
.	O

Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	S-Protein
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	S-Protein
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	B-Protein
-	I-Protein
Myc	I-Protein
interactor	E-Protein
.	O

We	O
further	O
show	O
that	O
Nmi	S-Protein
interacts	O
with	O
all	O
STATs	O
except	O
Stat2	S-Protein
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL	B-Protein
-	I-Protein
2	E-Protein
and	O
IFNgamma	S-Protein
,	O
and	O
demonstrate	O
that	O
Nmi	S-Protein
augments	O
STAT	O
-	O
mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O

Interestingly	O
,	O
Nmi	S-Protein
lacks	O
an	O
intrinsic	O
transcriptional	O
activation	O
domain	O
;	O
instead	O
,	O
Nmi	S-Protein
enhances	O
the	O
association	O
of	O
CBP	O
/	O
p300	O
coactivator	O
proteins	O
with	O
Stat1	S-Protein
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP	O
/	O
p300	O
can	O
augment	O
IL	B-Protein
-	I-Protein
2	E-Protein
-	O
and	O
IFNgamma	S-Protein
-	O
dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	S-Protein
can	O
potentiate	O
STAT	O
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	O
-	O
specific	O
transcription	O
factors	O
.	O
